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ABSTRACT OF DISSERTATION

THE ROLE OF ASTROCYTIC CALCINEURIN ACTIVATION AND DOWNSTREAM
SIGNALING IN NEURODEGENERATIVE DISEASES
Calcineurin (CN) is a calcium (Ca2+)-sensitive serine/threonine protein
phosphatase that plays a significant role in several cell signaling pathways, and has
been implicated in many neurodegenerative diseases including Alzheimer’s disease
(AD) and vascular cognitive impairment and dementia (VCID). Although normally found
in neurons, CN also appears at high levels in activated astrocytes under conditions of
injury and disease. To elucidate the role of astrocytic calcineurin signaling in
neurodegenerative diseases, our lab has used primary rat astrocytes, transgenic and
diet-induced mouse models of dementia, and human tissue biospecimens from
confirmed AD and VCID cases.
To better understand mechanisms for aberrant activation of CN during injury and
disease, we created a custom antibody that selectively identifies a proteolyzed,
constitutively active CN fragment. Immunolabeling in human biospecimens was done to
determine which cell types express high levels of CN proteolysis and hyperactivation.
Our results revealed extensive proteolysis of CN in activated astrocytes near pathologic
hallmarks of AD (Aβ plaques) and VCID (microinfarcts). When a similar activated CN
fragment was expressed in hippocampal astrocytes of healthy adult rats using adenoassociated virus (AAV) vectors, we observed suppressed function of CA3-CA1 excitatory
synapses, suggesting that proteolytic activation of CN in astrocytes is a key mechanism
for driving neuronal dysfunction in neurodegenerative diseases.
To explore the interaction between astrocytic CN and a possible downstream
signaling target, we studied the hemichannel-forming protein, connexin43 (Cx43).
Previous work has shown that serine 368 near the C terminus of Cx43 is
dephosphorylated by CN. Here, we found that dephosphorylation of ser368 was
increased in human hippocampal specimens from subjects diagnosed with mild cognitive
impairment (MCI). Dephospho-Cx43 levels were correlated, within subject, to elevated
levels of CN proteolysis and signaling. Moreover, dephosphorylation of Cx43 could be
mimicked in rat primary astrocyte cultures using both exogenous Ca2+ mobilizers
(phorbol ester/ionomycin) and endogenous inflammatory mediators (IL-1β), found
previously to activate CN in astrocytes. Finally, we created a custom peptide (43Gap52)
that encompasses Ser368 and mimics a portion of the C-terminus of Cx43. 43Gap52
prevented IL-1β-mediated dephosphorylation of Cx43, but did not prevent CN-dependent
activation of NFAT transcription factors, suggesting that 43Gap52 selectively disrupts

CN/Cx43 interactions. Using 43Gap52 and the commercial CN inhibitor cyclosporin A
(CsA), we found that blockade of CN/Cx43 interactions reduced hemichannel
permeability in primary astrocytes following treatment with IL-1β, suggesting that
aberrant CN activation in astrocytes may negatively affect neurons via interactions with
Cx43-containing hemichannels.
To more clearly understand CN/NFAT signaling in VCID we used a diet-induced
model of hyperhomocysteinemia (HHcy) that drives vascular pathology. Using AAVmediated gene delivery, we injected mice with an astrocyte-targeted inhibitor of
CN/NFAT binding (Gfa2-Egfp-VIVIT) or a control virus (Gfa2-Egfp). These mice were
further split into two groups, one fed with the HHcy diet and one fed with control diet.
Experiments are in progress to assess endpoint measurements including LTP and
synaptic strength, RAWM behavior testing, as well as a panel of biochemical
measurements.

KEYWORDS: Astrocyte, Calcineurin, Neuroinflammation, Alzheimer’s disease, Vascular
cognitive impairment and dementia
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CHAPTER I: NEURODEGENERATIVE DISEASE, NEUROINFLAMMATION,
ASTROCYTES, AND CALCINEURIN SIGNALING: A REVIEW

1

1.1 Neurodegenerative disease
As the world makes advances in both medical technology and healthcare, we see an
increase in the aging population. Unfortunately, with the increase in life expectancy we
see an increase in the number of people that develop neurodegenerative diseases.
Neurodegenerative disease is a broad term that describes a disease characterized by
chronic and progressive loss of both structure and function of neurons: e.g. amyotrophic
lateral sclerosis (ALS) or Parkinson’s disease (PD). Although the symptoms vary greatly
with each individual disease, individuals with neurodegenerative diseases typically show
some type of cognitive and/or motor deficits. It is believed that distinct
neurodegenerative diseases are driven by unique pathological features (e.g. prions in
Creutzfeldt-Jakob disease, amyloid in Alzheimer’s disease, microinfarcts in vascular
dementia) that lead to the breakdown of neuronal structure and function. Despite
differences in pathogenic mechanisms, nearly all neurodegenerative diseases are
unified by the appearance of neuroinflammation (Chen et al. 2016), involving feedforward cycles of cytokine production and neuroglial “activation”. For the scope of this
dissertation, I will focus on the role of activated astroglia in two of the most common
causes of neurodegeneration and dementia: Alzheimer’s disease (AD) and
cerebrovascular disease.

1.1.1

Alzheimer’s disease
AD is a devastating neurodegenerative disorder characterized by progressive

cognitive deficits, marked personality changes, and gradual loss of everyday skills and
functions. As of 2015, over 5.4 million people in the United States suffer from AD and
that number is expected to increase to 16 million by 2050. Moreover, in 2016 the total
direct cost of caring for individuals with AD in the United States alone is an estimated
2

$236 billion. While rates of many other diseases (i.e. cardiovascular disease, stroke, and
breast cancer) have declined, the prevalence of AD has increased at the alarming rate of
71% between 2000 and 2013. Furthermore, current medications on the market have
failed to prevent or cure AD (Alzheimer’s Association, 2016 Facts and Figures). It is
imperative that we develop treatments that will prevent, or at the very least slow the
progression of AD in order to avoid both health and financial crises. Finding effective
treatments has proven difficult given that the exact molecular mechanisms responsible
for the onset and progression of AD remain poorly understood.
In clinic, AD patients present with some degree of learning and memory
impairment (Selkoe, 2001; Mattson, 2004) although symptoms vary from person to
person. To make a clinical diagnosis of AD, physicians most often use behavioral or
cognitive examinations but can additionally use imaging techniques i.e. positron
emission tomography (PET) imaging as well as protein biomarkers from cerebrospinal
fluid (CSF) (Anoop et al., 2010; Counts et al., 2016). It should be noted that a final and
definitive diagnosis of AD cannot be made until brain tissue is examined at autopsy,
where macroscopic examination can reveal brain atrophy along with severe neuronal
loss, and microscopic examination can reveal the two pathologic hallmarks of AD—beta
amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) (Braak and Braak, 1991).
Neurofibrillary tangles are intraneuronal aggregations of hyperphosphorylated
tau, a microtubule-stabilizing protein that is abundant in neurons (Avila et al., 2004).
Hyperphosphorylation of tau can cause disintegration of microtubules that leads
disrupted axonal transport and synaptic dysfunction (Maccioni et al, 2001). Additionally,
studies have shown that tau can aberrantly associate with ribosomes in AD, leading to
decreased synthesis of synaptic proteins that ultimately contributes to synaptic
dysfunction (Meier et al., 2016). Aβ plaques are extracellular aggregations of cleaved
amyloid peptides. These peptides are produced by the cleavage of the membrane3

spanning amyloid precursor protein (APP). Normally, APP is cleaved extracellularly by αsecretase which releases a non-toxic, soluble fragment (sAPPα) (Nunan and Small,
2000). However, with AD, APP is cleaved extracellularly by β-secretase (BACE) followed
by intra-membrane cleavage by γ-secretase which releases toxic Aβ fragments from the
membrane (Haass and Selkoe, 1993; Nunan and Small, 2000). These fragments can
remain monomeric or assemble into oligomers, the most toxic form of Aβ, as well as
fibrils that form Aβ plaques. All forms are found in AD (Irvine et al., 2008), and while
some studies suggest disruption of synaptic function as the main mechanism of Aβ
toxicity (Shankar et al., 2008), the exact mechanisms remain poorly understood.
The most widely accepted hypothesis for the mechanisms that lead to memory
loss in AD is known as the “amyloid cascade”. In this model, increased production of
toxic Aβ oligomers interferes with neuronal synaptic function, resulting in formation of Aβ
plaques, neurite atrophy, activation of neuroinflammatory responses (astrocyte and
microglial activation), and hyperphosphorylation of tau that eventually culminates in a
dementia with hallmark plaque and tangle pathology (Hardy and Higgins, 1992;
Lovestone, 2000). However, as treatments that target Aβ clearance or degradation have
been largely ineffective at improving cognitive function, it is becoming more accepted
that a combinatorial approach to AD that targets mechanisms beyond or in addition to
Aβ may prove most effective. The majority of this dissertation will focus on the
neuroinflammatory response, namely astrocyte activation, as a possible target for AD
therapeutics.

1.1.2

Cerebral small vessel disease
Cerebral small vessel disease (SVD) describes a group of pathologic processes

that affects arterioles, capillaries, and venules of the brain. Most commonly, this
describes arteriolosclerosis and cerebral amyloid angiopathy (CAA). Damage to the
4

small vessels can result in white matter lesions (WMLs), lacunar infarcts, and cerebral
hemorrhages which can be detected easily by neuroimaging, and thus SVD is often
used to describe the above pathologies (Pantoni, 2010). Different studies have
suggested that both macroscopic and microscopic infarcts are sufficient on their own to
drive vascular cognitive impairment and dementia (VCID) (Smith et al., 2012). The
extent of cognitive impairment, however, may depend on number of infarcts as well as
brain region affected (Gorelick et al., 2016).
VCID is not only the second leading cause of dementia behind AD, but is also a
frequent comorbidity with AD, with up to 40% of patients presenting with a mixed
dementia e.g. AD and VCID (Dubois and Hebert, 2001; Kammoun et al., 2000; Korczyn
et al., 2012). Moreover, some evidence suggests that AD and VCID pathology may act
synergistically, requiring less of either pathology to express a state of dementia
(Schneider and Bennett, 2010). Risk factors for VCID often overlap with traditional risk
factors for stroke or cardiovascular disease and can include hypertension, diabetes,
hyperhomocysteinemia, and arterial stiffness (Gorelick et al., 2011).
Due to the heterogeneity of the disease, patients present in clinic with varying
symptoms of cognitive impairment. The lack of a precise and uniform pathologic
definition for VCID presents somewhat of a challenge as the gold standard for diagnosis
involves a neuropathological examination. However, physicians are generally able to
make a diagnosis based on a combination of neuropsychological examinations (focused
more on executive function than on learning and memory), brain imaging techniques
(Peca et al., 2013), and more recently, an assessment of biomarkers in the CSF.
Pathologic features of VCID may be any single or combination of brain vascular factors
that includes small vessel disease (SVD) including WMLs, infarcts (lacunar, macro-, and
micro-), as well as microbleeds (Gorelick et al., 2011).

5

The mechanisms by which cerebrovascular factors contribute to dementia is still
not greatly understood. Pathologies such as microhemorrhages and WMLs may
represent direct tissue damage i.e. breakage of vessels leading to bleeds or
degeneration of white matter resulting in a lesion. For example, several studies have
implicated the matrix metalloproteinases 2 and 9 (MMP-2/MMP-9) in the induction of
cerebral hemorrhages (Klein and Bischoff, 2011; Candelario-Jalil et al., 2011;
Hernandez- Guillamon et al., 2012). Moreover, VCID pathologies can be both focal (i.e.
single infarct or lesion) as well as diffuse (i.e. widespread hypoxia or oxidative stress).
These pathologies can have profound and devastating impacts on the integrity of the
neurovascular unit i.e. the junction of vessel endothelial cells, astrocyte endfeet, and
pericytes, as well as on the BBB and white matter. Whether on its own or as a
comorbidity with AD, it is critical to find effective therapeutics to slow or treat the multivaried pathologies of VCID.

1.2 Neuroinflammation
Neuroinflammation is associated with aging, injury, and many neurodegenerative
disorders, including AD and VCID (Akiyama et al., 2000; Skaper, 2007). The general
hallmarks of neuroinflammation include altered number of neuroglia, change in glial
morphology, as well as increased expression of cytokines, chemokines, reactive oxygen
species, and other inflammatory mediators (Wisniewski and Wegiel, 1991; Van Eldik and
Griffin, 1994; Mrak and Griffin, 2001b, a; Heneka et al., 2015). Acutely, the inflammatory
response can isolate and facilitate the repair of sites of injury, pathogen invasion, and
protein aggregation. However, it is becoming increasingly clear that a chronic state of
neuroinflammation is detrimental to neuronal health and synaptic function (Griffin et al.,
1998; Griffin and Mrak, 2002; Mrak and Griffin, 2005b).
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The two predominant glial cell types are microglia and astrocytes, both of which
are associated with neuroinflammation. Microglia are macrophages that circulate
throughout the brain foraging for invading pathogens or foreign molecules which they
remove via phagocytosis. Additionally, with neuroinflammation, microglia undergo
complex morphological changes where they secrete cytokines, chemokines,
complement factors, and reactive oxygen species which aid in recruiting more
monocytes and macrophages to the site of injury (Akiyama et al., 2000; Griffin, 2006).
Similarly, with neuroinflammation, astrocytes undergo a hypertrophic activation where
they increase production of pro-inflammatory factors (Sama et al., 2008; Fuller et al.,
2009; Sofroniew, 2009; Fuller et al., 2010; Sofroniew and Vinters, 2010; Colombo and
Faring, 2016). With a severe and/or chronic insult such as AD or VCID, the production of
pro-inflammatory mediators is nearly continuous, resulting in a positive, feed-forward
cycle between astrocytes and microglia that is accompanied by a likely detrimental state
of neuroinflammation.
For example, targeting pro-inflammatory molecules e.g. TNFα, p38 MAPK, or IL1β in a mouse model of AD revealed improved functional and reduced pathological
outcomes (Munoz et al., 2007; McCoy and Tansey, 2008; Shaftel et al., 2008; Munoz
and Ammit, 2010; Kitazawa et al., 2011; Bachstetter et al., 2012), suggesting that
neuroinflammation is not only a byproduct of the disease but is also playing a significant
role in the progression of AD pathophysiology. Other studies using a diet-induced model
of VCID have found an elevated pro-inflammatory cytokine panel i.e. IL-1β, IL-6, and
TNFα in mice on the diet compared to control mice (Hofmann et al., 2001; Sudduth et
al., 2013b), suggesting that neuroinflammation is also a significant contributor to VCID
pathology.
In support of these findings, data from epidemiological studies have shown that
people who take long-term courses of common anti-inflammatory agents i.e. non7

steroidal anti-inflammatory drugs (NSAIDs) have a delayed or decreased risk of
developing AD (Andersen et al., 1995; Rich et al., 1995; McGeer et al., 1996; Lee et al.,
2010). However, controlled trials have not been able to replicate these findings (Aisen et
al., 2003; Reines et al., 2004), possibly due to poor therapeutic targeting or poor drug
delivery timing, given that neuroinflammation is a complex process involving several cell
types and mediators. Only several pathways have been well-studied to date, so targeting
neuroinflammation should not be disregarded in the search for a viable treatment for
neurodegenerative diseases.

1.3 Mouse models of neurodegeneration
A multitude of mouse models exist to study AD. The most widely-used models
involve a genetic modification of amyloid processing proteins (APP and/or PS1). Models
include but are certainly not limited to Tg2576 (Hsaio et al., 1996), APP/PS1 transgenic
(Jankowsky et al., 2004), APP/PS1 knock-in (KI) (Flood et al., 2002), 5xFAD (Oakley et
al., 2006), and the 3xTg-AD (Oddo et al., 2003). Although these models vary slightly in
their mutations within the genes, they all develop parenchymal Aβ plaques and deficits in
spatial working memory albeit the timing and extent to which they develop these differs
(Elder et al., 2010; Webster et al., 2014). Unlike the others mentioned above, the 3xTgAD model not only has mutations in amyloid processing genes, but also contains a
mutation in the tau gene, making it a more representative model of AD with both amyloid
and tau pathology. In addition to the amyloidogenic models of AD, some researchers
also use tauopathic models. These can include the P301S (Gotz et al., 2001a) and the
rTg (tauP301L) 4510 (Gotz et al., 2001b) mice. Again, although timing of development
may differ these mice have profound NFT formation, neuronal loss, as well as cognitive
decline (Bryan et al., 2009).
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While numerous AD mice are available, some concerns come to mind about their
usefulness as a model system. One, while these mice may exhibit striking pathology
their cognitive deficits are only lackluster. Moreover, many interventions and
therapeutics that are efficacious in mouse models of AD have shown underwhelming
results in human clinical trials, bringing into question whether these models are
translatable (Bryan et al., 2009). Some research suggests better model systems for
studying AD e.g. canines (Cummings et al., 1993; Head 2013).
Unlike AD, the heterogeneity of disease pathology that is seen with VCID presents a
huge challenge in developing appropriate models. Numerous mouse and/or rat models
have been developed to study the different causes of VCID, which has recently been
well-reviewed (Gooch and Wilcock, 2016). The bilateral common carotid artery stenosis
(BCAS) mouse model is the most widely-used to study subcortical ischemic vascular
dementia (Nakaji et al., 2006; Shibata et al., 2007; Yoshizaki et al., 2008; Bink et al.,
2013), and less commonly used is the asymmetrical common carotid artery stenosis
(ACAS) mouse model (Bink et al., 2013; Hattori et al., 2015). Several genetic variants
have been developed to study cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) (Hainsworth and Markus, 2008; Wallays et
al., 2011; Cognat et al., 2014; Ehret et al., 2015), which is the most common genetic
cause of VCID. Type 2 diabetes mellitus (T2DM) mice develop vascular pathologies in
addition to AD-like neuropathologies (Jiwa et al., 2010; Takeda et al., 2010; Niedowicz et
al., 2014). Several transgenic models exist to study cerebral amyloid angiopathy (CAA)
(Davis et al., 2004; Herzig et al., 2004; Miao et al., 2005; Kumar-Singh, 2009;
Hernandez-Guillamon et al., 2011; Kulic et al., 2012). Additionally, cerebral SVD is most
commonly studied in a spontaneously hypertensive (SHR) rat model (Jiwa et al., 2010;
Joutel et al., 2010; Yun et al., 2014). Several varying occlusion models have been
developed in rats to study cerebral hypoperfusion (Sakai et al., 1996; Roof et al., 2001;
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Neto et al., 2005; Pereira et al., 2012). However, none are optimal as they lack
metabolic similarity to humans i.e. white matter vascular injury and hypertension (Snyder
et al. 2015).
Some genetic models exist to study HHcy-induced VCID which are achieved by
inducing mutations in enzymes that are critical for converting homocysteine in the
transsulfuration pathway, including cystathionine β-synthase (Baumbach et al., 2002)
and methylenetetrahydrofolate reductase (Devlin et al., 2004). These models can be
helpful for studying the microhemorrhage component of VCID. However, unlike the dietinduced model which will be described in the following section, transgenic models do not
easily facilitate the observation of neurodegenerative disease comorbidities. Thus, the
diet-induced HHcy mouse appears to be a valuable model for studying VCID and its
comorbidities.

1.3.1 Using excess homocysteine to drive VCID in a mouse model
Homocysteine is a sulfur-containing, non-essential amino acid produced in all cells
that is a product of normal folate and methionine metabolism. Homocysteine is a
transient product that is normally converted to cystathionine via the transsulfuration
pathway. With some aging, injury, and even some rare genetic mutations, levels of
homocysteine can become elevated in the plasma, which is referred to as
hyperhomocysteinemia (HHcy). Buildup of homocysteine in the plasma can occur as a
result of mutations in certain enzymes in the transsulfuration pathway i.e. cystathionineβ-synthase (CBS) or methylenetetrahydrofolate reductase (MTHFR) as well as from a
deficiency of critical co-factors e.g. vitamins B6, B12, and folate and/or an excess of
methionine, a precursor for homocysteine (Stipanuk and Ueki, 2011). This dissertation
will focus on a diet-induced HHcy model to study VCID.
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A Teklad custom research diet (Harlan laboratories) has been developed to induce
HHcy, which is deficient in folate, B6, and B12, and also has excess methionine (7.7 g/kg)
versus control diet (3.0 g/kg). Levels of other vitamins and minerals, as well as protein
(195 g/kg) are uniform across the HHcy and control diets. Studies suggest that animal
placed on the HHcy diet for a minimum of 11 weeks develop a moderate HHcy, defined
by plasma homocysteine levels between 30-100 µmol/L (Ernest et al., 2005). This HHcy
diet is sufficient to cause cognitive decline (Troen et al., 2008), inflammation (Hoffman et
al., 2001), as well as increased microhemorrhages (Sudduth et al., 2013b). Moreover,
mice from alternative disease models e.g. AD (Sudduth et al., 2014; Weekman et al.,
2016) can be placed on the diet, making it an easily-controlled and valuable model for
studying not only VCID but also its comorbidities in a mouse model.

1.4 Astrocytes
As one of the most abundant cell types in the brain (Chen and Swanson, 2003), the
role and contribution of astrocytes to AD, VCID, and other neurological disorders
remains underappreciated. Astrocytes are no longer considered as only “support” cells,
as they perform critical functions including but not limited to maintenance of neurons and
synapses, regulation of ions, metabolites, and glutamate, as well protection of the bloodbrain barrier (Pekny and Nilsson, 2005; Sofroniew and Vinters, 2010; Pekny et al., 2016;
Pekny and Pekna, 2016). As mentioned above, astrocytes are also one of the key
players in the neuroinflammatory response, where they undergo a hypertrophic
morphological change and increase secretion of pro-inflammatory cytokines in a process
known as astrocyte activation (Fuller et al., 2009; Sofroniew, 2009; Fuller et al., 2010;
Sofroniew and Vinters, 2010). Acutely, astrocyte activation may serve to isolate areas of
injury, recruit additional support cells, and prevent any further damage. However, chronic
astrocyte activation, as is seen with AD or VCID, may result in a damaging feed-forward
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production of pro-inflammatory cytokines, and also in a loss of extracellular glutamate
regulation (Sofroniew, 2009; Fuller et al., 2010). Several studies have been performed
using mouse models of AD and VCID to target signaling pathways in astrocytes known
to result in astrocyte activation. Modulation of astrocyte signaling pathways has been
shown to have both beneficial and detrimental effects on neural function, suggesting that
activated astrocytes have a complex phenotype and may play a myriad of roles during
the progression of neurodegenerative disease. These observations suggest that the
refinement of astrocyte-targeting strategies may lead to more effective treatments of
neurodegenerative conditions such as AD and VCID. Moreover, work from our lab
suggests that astrocytic calcineurin (CN) signaling may be a promising target for
ameliorating the synaptic deficits seen in neurodegeneration (Furman et al., 2012;
Furman et al., 2016; Pleiss et al., 2016; Pleiss et al., in preparation).

1.5 Calcineurin
CN is an exquisitely calcium (Ca2+)/calmodulin (CaM)-dependent serine/threonine
protein-phosphatase that is expressed in most mammalian cell types, but found in
particularly high levels in the CNS (Klee, 1991). In healthy brain tissue, CN is most
abundant in neurons where it performs critical functions in the maintenance of synaptic
viability and plasticity. In healthy neural tissue, intracellular Ca2+ levels are low and
tightly regulated; however, under conditions of aging, injury, and disease such as AD
and vessel damage, cytosolic Ca2+ levels are elevated and regulation is often unchecked
(Abdul et al., 2010). Hyperactivation of CN due to aberrant changes in neuronal Ca2+
levels, has deleterious effects on synapses and neuronal viability, such as activation of
apoptosis cascades (Springer et al., 2000; Norris et al., 2005; Sama et al., 2008). On the
other hand, expression of CN in astrocytes is incredibly low in healthy tissue but under
neurodegenerative conditions with profound astrocyte activation, there is a striking
12

increase in CN expression (Hashimoto et al., 1998; Norris et al., 2005; Celsi et al., 2007;
Abdul et al., 2009; Pleiss et al., 2016). In mouse models of AD as well as human AD
tissue, CN is intensely labeled in astrocytes around amyloid deposits later in the disease
stage (Norris et al., 2005; Pleiss et al., 2016). In mouse models of VCID as well as
human VCID tissue, CN is strikingly labeled in astrocytes surrounding microinfarcts
(Pleiss et al., 2016).
Normally, minor changes in intracellular Ca2+ levels result in increased activation of
CaM that in turn results in increased activation of CN. Aberrant and unchecked Ca2+
dyshomeostasis can lead to activation of calpain (CP), a Ca2+-dependent cysteine
protease, which results in a constitutive and irreversible activation of CN (ΔCN) (see
Figure 1.1). Proteolyzed calcineurin has been implicated in activation of apoptosis
cascades, in part through dephosphorylation of the proapoptotic factor BAD (Wang et
al., 1999; Springer et al., 2000) Furthermore, Ca2+ dysregulation has been associated
with dendritic spine retraction and synaptic dysfunction, likely due to the actions of CN
on cytoskeletal proteins and glutamate receptors (Halpain et al., 1998; Shankar et al.,
2007; Tackenberg and Brandt, 2009; Wu et al., 2010). In Chapter II, I outline studies that
used a novel antibody reagent to show that CN proteolysis occurs extensively in
activated astrocytes associated with AD and VCID pathologic features, suggesting that
hyperactivation of CN signaling pathways in astrocytes is a critical component of both
diseases, possibly through activation of neuroinflammatory cascades. CN interactions
with downstream targets, such as NF-κB, have been implicated in production of
inflammatory mediators (e.g. IL-2) (Crabtree, 2001). As outlined in Chapters III and IV,
work from our lab, and others, suggest that the transcription factor NFAT and the
hemichannel-forming protein, connexin 43, may be particularly important for coupling CN
hyperactivity to astrocyte-dependent neurologic dysfunction.
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1.5.1

NFATs

Although they have been extensively studied in peripheral immune cells, little was
known about the role of the nuclear factor of activated t-cells (NFATs) in the CNS until
recently. NFATs are transcription factors that are normally found in the cytosol in a
heavily-phosphorylated state (Crabtree and Olson, 2002). With cellular activation,
NFATs translocate to the nucleus following CN-dependent dephosphorylation and
exposure of a nuclear localization peptide. Once in the nucleus, NFATs promote the
synthesis of pro-inflammatory cytokines, chemokines, and mediators such as IFNγ or
TNFα (McCaffrey et al., 1994; Stankunas et al., 1999; Avni et al., 2002; Palanki, 2002;
Kitazawa et al., 2004; Demuro et al., 2005; White et al., 2005; Shankar et al., 2008) (see
Figure 1.2). NFATs remain in the nucleus in an activated state until they are rephosphorylated by protein kinases and exported back to the cytosol. Thus, CN/NFAT
interactions play a critical role in the peripheral immune/inflammatory response.
In astrocytes, CN and NFAT appear to have many similar functions. Proinflammatory factors, excitotoxins (e.g. glutamate and ATP), and pathogenic oligomers
of Aβ and α-synuclein robustly stimulate CN/NFAT activity in a variety of neural cell
types including astrocytes (Sama et al., 2008; Abdul et al., 2009). Once activated,
CN/NFAT signaling triggers the production of cytokines that are associated with
neurodegeneration i.e. IL-6 and TNFα, and has also been shown to downregulate
glutamate transporter levels (Van Wagoner et al., 1999; Fernandez et al., 2007; Sama et
al., 2008). This can result in a feed-forward cycle of toxic cytokine production and an
accumulation of glutamate around synapses, both of which can be detrimental to
neurons. Several animal models of injury and disease using commercial calcineurin
inhibitors (CNIs) have revealed a reduction of neuroinflammation (Taglialatela et al.,
2009; Hong et al., 2010; Rozkalne et al., 2011; Saganova et al., 2012); however, CNIs
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have wide volumes of distribution and numerous off-target effects (Marks, 1996; Aliabadi
et al., 2007) and thus provide little information about the specific impact of CN signaling
in astrocytes. Our work has overcome these difficulties using a small peptide (VIVIT)
(Aramburu et al., 1999) directed to astrocytes using adeno-associated virus to
specifically inhibit interactions between CN and NFAT. In mouse models of both AD and
VCID, inhibition of CN/NFAT interactions ameliorated synaptic function, suggesting that
CN/NFAT-mediated activation in astrocytes plays a detrimental role in the
commencement and/or progression of neurodegenerative diseases such as AD or VCID
(Furman et al. 2012; Pleiss et al. in preparation). Using astrocyte-specific AAV-Gfa2VIVIT to inhibit CN/NFAT in a diet-induced model of VCID will be further explored in
Chapter III of this dissertation.

1.5.2

Connexin43
Connexins are membrane-spanning proteins that form hexameric pores used for

the transport of small molecules and ions. When unopposed, these hexamers form
hemichannels (HCs) that allow for the indiscriminate flow of potassium ions, water, and
glutamate between the cytosol and extracellular milieu. A hexamer in direct contact with
another hexamer on an adjacent cell, forms a cell-to-cell conduit known as a gap
junction (GJ), which allows the shuttling and transfer of small molecules and ions
between cells (see Figure 3). In healthy brain tissue, HCs are normally in a closed state
while GJs are normally open (Dbouk et al., 2009; Takeuchi and Suzumura, 2014; Moore
and O’Brien, 2015; Olsen et al., 2015). However, with neurological insults and diseases
this can be reversed, resulting in a leaking of ions/molecules e.g. K+ and glutamate into
the extracellular milieu and a loss of communication between cells, both being potentially
detrimental to neurons and synapses (Orellana et al., 2009; Koulakoff et al., 2012;
Orellana et al., 2012).
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Connexin43 (Cx43) is by far the most abundant and ubiquitously expressed
connexin across all tissues, and astrocytes are no exception (Solan and Lampe, 2009).
The cytosolic C-terminus of Cx43 is thought to be a critical region for regulatory and
protein-protein interactions, and is highly regulated by several kinases (Dbouk et al.,
2009) e.g. protein kinase C (PKC) (Lampe and Lau, 2000) and mitogen-activated protein
kinase (MAPK) (Seo et al., 2006). Several studies have shown that changes in
phosphorylation state are associated with neurodegenerative conditions such as AD
(Lampe and Lau, 2004; Solan and Lampe, 2009; Solan and Lampe, 2014). Work from
our lab and others has shown that serine 368 within the Cx43 C-terminus is strongly
sensitive to CN activity (Li and Nagy, 2000; Tence et al., 2012; Pleiss et al., in
preparation). Using an antibody that specifically recognizes Cx43 when
dephosphorylated at Ser368, researchers found that levels of dephosphorylated Cx43
were increased in cell cultures under hypoxic conditions. Dephosphorylation of Cx43
was blocked by the addition of commercial CN inhibitors to the culture medium i.e.
FK506 or cyclosporin A (Li and Nagy, 2000). Together, these results suggest that
targeting CN/Cx43 interactions in astrocytes may be a valuable strategy to prevent
breakdown of intercellular communication and synaptic function (via HC leakage) during
the progression of AD. Chapter IV explores this possibility using human postmortem
hippocampal tissues, primary astrocyte cultures, and novel reagents for disrupting
CN/Cx43 interactions.

1.6 Summary
Neurodegenerative diseases i.e. AD and VCID are often accompanied by robust and
striking neuroinflammation, which may significantly contribute to disease processes.
Upon activation, astrocytes express unfavorable inflammatory properties and lose many
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protective properties, which appears to be mediated, in part, by the activation of CN. The
work in my dissertation investigates the role of CN activation and its interactions with
downstream targets in neurodegenerative diseases, specifically focusing on AD and
VCID. This was accomplished using rat primary astrocyte cell cultures, mouse models of
both AD and VCID, as well as human biospecimens from confirmed cases of AD and
VCID. My work also explored the use of several novel compounds to study CN activation
and to inhibit CN’s interactions with its downstream targets. Results showed that CN
activation and signaling cascades may play a significant and central role in initiation
and/or development of neurodegenerative disease processes like AD and VCID.
Together, results suggest that CN activation/signaling is a valuable molecular target for
neurodegenerative diseases like AD and VCID.
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Figure 1.1 Normal versus Aberrant CN Activation. (A) In healthy tissue, CN is
extremely sensitive to small changes in intracellar Ca2+ levels. Under low intracellular
Ca2+ levels, an auto-inhibitory domain (AID) covers the catalytic binding site, maintaining
CN in an inactive state. Rises in intracellular Ca2+ levels cause displacement of the AID,
which allows CaM to bind to CN and renders it active. (B) However, with
neurodegenerative diseases a profound Ca2+ dysregulation occurs resulting in activation
of the calcium-dependent cysteine protease, calpain (CP). CP cleaves the AID from CN,
exposing the catalytic site and launching it into a state of constitutive and unchecked
phosphatase activity independent of intracellular Ca2+ levels.
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Figure 1.2 NFAT translocation into the nucleus promotes transcription of proinflammatory factors. Rises in intracellular Ca2+ levels lead to activation of CN via
binding of CaM. CN phosphatase activity dephosphorylates the nuclear factor of
activated t-cells (NFAT), allowing it to translocate into the nucleus where it promotes the
transcription of pro-inflammatory factors e.g. TNF-α and IFN-γ.
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Figure 1.3 Connexin43 hemichannels and gap junctions help form the astrocytic
network. Unopposed connexin43 hexamers form hemichannels (HCs) that allow for the
passage of small molecules e.g. K+ ions and glutamate between the cell and the
extracellular milieu. When connexin43 hexamers are in direct contact with one another,
they form gap junctions (GJs) that allow for direct cell-to-cell communication. Both HCs
and GJs play a critical role in helping astrocytes maintain the neural metabolic
homeostasis.
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2.1 Introduction
Mounting evidence suggests that the hyperactivation of the Ca2+/ calmodulin (CaM) dependent protein phosphatase calcineurin (CN) is a key contributor to the pathophysiologic and clinical symptoms of Alzheimer’s disease (AD) and other
neurodegenerative disorders (Norris et al., 2005; Reese et al., 2008; Abdul et al., 2009;
Wu et al., 2010; Furman et al., 2012; Rojanathammanee et al., 2013; Rojanathammanee
et al., 2015; Taglialatela et al., 2015). The detrimental effects of CN dysregulation may
arise through unique alterations in neurons and glial cells (Abdul et al., 2010; Reese and
Taglialatela, 2011; Furman and Norris, 2014). In astrocytes and microglia, CN controls
immune/inflammatory phenotypes through activation of key transcription factors
including nuclear factor of activated T cells (NFAT), nuclear factor κB (NFκB), and
FOXO, among others (Fernandez et al., 2007; Canellada et al., 2008; Sama et al., 2008;
Abdul et al., 2010; Fernandez et al., 2012; Fernandez et al., 2016). Previously, we
showed that the selective blockade of astrocytic CN/NFAT signaling with the NFATinhibitory peptide, VIVIT, suppresses markers of glial activation, alleviates amyloid
pathology, and protects against cognitive deficits in experimental models of AD (Sama et
al., 2008; Abdul et al., 2009; Furman et al., 2012) and prevents synapse dysfunction in
models of AD and acute brain injury (Furman et al., 2012; Furman et al., 2016). These
results suggest that astrocytes are a key locus of hyperactive CN signaling during the
progression of AD. However, little is known about the mechanisms that lead to or sustain
aberrant astrocytic CN/NFAT signaling.
Hyperactivation of CN in other cell types, including neurons and cardiomyocytes,
can arise from the disruption, or proteolytic removal, of a critical autoinhibitory domain
(AID) located near the C-terminus of the CN catalytic subunit (CN A) (for review, see
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Norris, 2014). Normally, when Ca2+ levels are low, the AID strongly limits phosphatase
activity until it is displaced from the catalytic site by Ca2+/CaM (Perrino et al, 1995).
Proteolytic removal of the AID by the cysteine protease, calpain (CP), can occur after
cellular insults and large surges in intracellular Ca2+ (Wu et al., 2004). Without the AID,
CN A is largely, and irreversibly uncoupled from local Ca2+ gradients, resulting in
elevated phosphatase activity, whether normal levels of Ca2+ are restored or not (Wu et
al., 2004). Many commercial antibodies to the C-terminus of CN A recognize full length
CN (FL-CN, ~60 kDa), but fail to detect CN proteolytic fragments (i.e. ΔCNs) because
the epitope is located in the region that is cleaved away. In contrast, N-terminus
antibodies identify both FL-CN and ΔCNs. Use of Western blot techniques and Nterminus CN antibodies has revealed the presence of ΔCNs in whole brain tissue under
several neurodegenerative conditions (Huang et al., 2005; Liu et al., 2005; Shioda et al.,
2006; Shioda et al., 2007; Wu et al., 2010; Rosenkranz et al., 2012). Previous work from
our group on human subjects with mild cognitive impairment revealed elevated
hippocampal levels of a ΔCN fragment in the 45-48 kDa range (Abdul et al., 2011). A
similar fragment was generated in mixed (neurons and glia) primary hippocampal
cultures, coincident with elevated NFAT activity and frank neuronal degeneration,
following treatment with oligomeric amyloid-β peptides. The appearance of ΔCN at early
stages of neurologic dysfunction suggests that CN proteolysis is more than a biomarker
of neurodegeneration, and may be an antecedent for later neurodegenerative events.
Unfortunately, because of the cell-type heterogeneity of whole brain homogenates, it’s
nearly impossible to discern where (i.e. in what cell type) CN proteolysis is occurring. In
immunohistochemical (IHC) applications, N terminus antibodies reveal the presence of
CN in multiple cell types, including activated astrocytes (Norris et al., 2005; Abdul et al.,
2009). However, it remains unclear whether the labeled CN is of the intact, full-length
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variety or of the proteolyzed, highly active variety. To resolve this issue, we generated
custom antibodies to CN A based on previously identified CP-cleavage sites (Wu et al.,
2004). One of these antibodies selectively detected a 45-48 kDa fragment (∆CN) in
Western blot assays. IHC investigations of human brain tissue revealed the presence of
∆CN in numerous astrocytes, especially those associated with Aβ deposits and
microinfarcts. Adeno-associated virus (AAV)-mediated delivery of a similar ΔCN
fragment to hippocampal astrocytes of healthy adult rats caused a reduction in CA1
synaptic strength. Together, the results are consistent with the hypothesis that CN
dysregulation in activated astrocytes is attributable, in part, to limited proteolysis.
Moreover, the presence of proteolyzed CN in astrocytes appears to be sufficient for
disrupting synaptic function, indicating a possibly critical mechanism for synaptic decline
in AD and other neurodegenerative conditions.

2.2 Methods
2.2.1 ∆CN antibody production and purification. Peptides based on known CP
dependent cleavage sites (Wu et al., 2004) were generated by PrimmBiotech (West
Roxbury, MA) and used to inoculate adult rabbits. Antisera from rabbits inoculated with
the peptide, ESVLTLK (amino acid sequence immediately upstream of the 48 kDa CN
cleavage site) detected a 45-48 kDa fragment in initial Western blot assays. The antisera
were then purified using a negative selection approach. In brief, the ESVLTLK peptide
was coupled to HiTrapTM NHS-activated HP columns (GE Healthcare, Little Chalfont,
United Kingdom) followed by addition of antisera. Antibodies were then eluted and
collected according to manufacturer instructions. Following a second round of columnpurification, the eluate was aliquoted and frozen for additional Western blot screening.
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2.2.2 Primary cell culture. Primary mixed (astrocytes and neurons) hippocampal
cultures were prepared from embryonic day 18 Sprague-Dawley rat pups as described
previously (Porter et al., 1997; Norris et al., 2006; Sama et al., 2008). Cells were
investigated at between 14 and 21 days in vitro (DIV). To generate CN proteolysis,
cultures plated in 35 mm dishes were treated for 24 h with synthetic oligomeric βamyloid 1-42 (Aβ1-42) peptides (~65 nM) prepared as described in our previous work
(Abdul et al., 2009; Abdul et al., 2011). Aβ1-42 was delivered in the presence or
absence of the CP inhibitor, calpeptin (10 μM), obtained from EMD Millipore (Gibbstown,
NJ). Calpeptin was added to cultures approximately 2 h prior to the addition of Aβ1-42.

2.2.3 Western blot analysis. At 24 h post- Aβ treatment, cells were homogenized in
high sucrose buffer and protein concentration determined using the Lowry method.
Samples were loaded onto a Bio-Rad gradient gel (4-20%) with protein concentrations
held constant across lanes. Proteins were resolved by electrophoresis and transferred to
PVDF membranes for Western blot analysis. Membranes were blocked then incubated
overnight at 4°C in the following primary antibodies: 1:3000 anti-CN-Aα (Millipore) and
1:1000 anti-∆CN (custom). Primary antibodies were labelled with appropriate HRPconjugated secondary antibodies and detected using the ECL Plus Western Blotting
system (GE Healthcare). Relative molecular weights of full length CN and ∆CN were
quantified using a Bio Rad Chemidoc XRS Gel imager and Quantity One Software
(Hercules, CA).
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2.2.4 Human biospecimens. Post-mortem brain specimens from the amygdala,
hippocampus, and superior and middle temporal gyri (SMTG) were obtained from the
University of Kentucky Alzheimer’s Disease Center (UK-ADC) Tissue Repository.
Amygdala and hippocampal specimens from 6 different AD cases and 2 different agematched control cases were investigated. SMTG biospecimens were from five individual
subjects. All subjects were participants in the UK-ADC Autopsy program. Postmortem
autopsy intervals for UK-ADC samples, including the ones used in this study, is
approximately 3 hours (e.g. see [Nelson et al., 2007; Abdul et al., 2009; Abdul et al.,
2011]). The presence of AD pathology (amyloid plaques and neurofibrillary tangles) and
vascular pathology (microinfarcts) in all human cases was confirmed by personnel in the
UK-ADC neuropathology core.

2.2.5 Histology. Paraffin-embedded SMTG sections were cut to ~8 μm thickness and
baked overnight at 40°C. Sections were deparaffinized in fresh Xylene and rehydrated
through a series of graded alcohols to water. Sections were dipped into Harris’s
hematoxylin for 4 minutes then rinsed in running water. Following a water rinse, sections
were dipped twice into acid alcohol, rinsed in running water, dipped twice into 1%
ammonia water, and rinsed in water for 10 minutes. Sections were dipped into Eosin
solution for 15-20 seconds and then dehydrated through graded alcohols, cleared using
Xylene, and mounted.

2.2.6 Immunohistochemistry. Amygdala, hippocampal, and SMTG specimens were
fixed in 10% formaldehyde, embedded in paraffin, and cut into ~8 µm thick sections.
Slides were baked in a 40°C oven overnight, deparaffinized using SafeClear (Fisher
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Scientific), and rehydrated through a series of graded alcohols to water. Slides were
boiled for 10 minutes in Borg Decloaker antigen retrieval solution, pH = 6.0 (Biocare
Medical) before blocking endogenous peroxidase activity with 3% hydrogen peroxide +
10% methanol. The slides were blocked (0.1 M Tris buffer with 0.1% Triton X-100 and
2% bovine serum albumin) and incubated overnight at 4°C in the following primary
antibodies: 1:25 rabbit polyclonal anti-∆CN; 1:500 mouse monoclonal anti-CN-Aα (Cterminus) (Sigma); 1:50 mouse monoclonal anti-Aβ (Vector Laboratories. Secondary
antibodies were added at a 1:200 dilution for 1 hour at room temperature as follows:
anti-mouse IgG + horse normal serum or anti-rabbit IgG + goat normal serum. Following
secondary antibody, signal was amplified with avidin-biotin complex for 1 hour at room
temperature and then detected using either DAB or SG substrates (Vector Laboratories).
Following dehydration through a series of graded alcohol and clearing (SafeClear),
slides were permanently mounted using VectaMount (Vector Laboratories) and
coverslipped.

2.2.7 Immunofluorescence. Amygdala, hippocampal, and SMTG sections were fixed in
4% paraformaldehyde and preserved in sucrose buffer. Slices were cut on a freezing
microtome to 50μM thickness. Free-floating sections were blocked (0.1 M Tris buffer with
0.1% Triton X-100 and 2% bovine serum albumin) and incubated overnight at 4°C with
primary antibodies including: 1:25 anti-ΔCN; 1:50 anti-GFAP directly conjugated to Alexa
594 (Cell Signaling); 1:100 anti-NeuN (Millipore). After washing, sections were incubated
1:500 in Alexa Fluor 488 or 594 secondary antibodies (Life Technologies). Fluorescent
sections were mounted with ProLong Gold Antifade Reagent with DAPI (Molecular
Probes) and coverslipped.
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2.2.8 Animals. Adult male Sprague Dawley rats were obtained from Harlan Laboratories
(Indianapolis, IN). Rats were held in standard laboratory cages under 12-h light/12-h
dark cycles in a pathogen free environment in accordance with University of Kentucky
guidelines. The animals had access to food and water ad libitum. All animal procedures
were conducted in accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and were approved by University of Kentucky
Institutional Animal Care and Use Committees.

2.2.9 Intrahippocampal delivery of adeno-associated virus (AAV). cDNA encoding
the first 398 amino acids of the CN Aα isoform (ΔCN), which lacks the Ca2+/CaM
binding domain and the AID (Kincaid et al., 1990), was subcloned into the polylinker site
of a hybrid pCI vector containing IRES2-DsRed-Express (Clontech, Mountain View, CA).
IRES-DsRed2 (control construct) or ΔCN-IRES-DsRed2 were then inserted into pAAV2Gfa104-EGFP (University of Pennsylvania Vector core) in place of EGFP. High titer
(1012 IFU/mL) AAV vectors (AAV-Gfa104-DsRed and AAV-Gfa104-ΔCN) were then
generated in the University of Kentucky Vector core using an AAV5 helper plasmid and
HEK293 cells. The Gfa104 promoter has been characterized previously, and has been
shown to drive transgene expression selectively in astrocytes of intact animals (Ortinski
et al., 2010; Cui et al., 2014), similar to that seen with the Gfa2 promoter (e.g. see
Furman et al., 2016).
Rats were placed in a stereotaxic frame (David Kopf Instruments Tujunga, CA) and
anesthetized with isoflurane (2.5%) throughout the surgery process. For each rat, AAVGfa104-DsRed and AAV-Gfa104-ΔCN were loaded into separate microinjectors and
delivered into alternate hemispheres, such that one hippocampus was treated with
Gfa104-DsRed and the other hippocampus was treated with Gfa104-ΔCN. Each
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hemisphere was injected with 4 µL of AAV (1012 IFU/mL) at 0.2 µL/min. Injection
coordinates were -3.8mm anteroposterior and +1.8mm mediolateral relative to bregma,
and -1.8mm dorsoventral relative to dura. DsRed visualization in formaldehyde-fixed
tissue sections was achieved using a rabbit polyclonal antibody to red fluorescent
protein (Abcam) and Alexa Fluor secondary antibodies as described above for human
sections.

2.2.10 Hippocampal slice electrophysiology. At 4 months after AAV injection, rats
were euthanized under CO2 anesthesia and decapitated. Brains were rapidly removed
and placed in ice-cold, oxygenated (95% O2, 5% CO2) artificial cerebrospinal fluid
(ACSF) containing (in mM) 124 NaCl, 2 KCl, 1.25 KH2PO4, 2 MgSO4, 0.5 CaCl2, 26
NaHCO3, and 10 dextrose (pH 7.4). Brains were hemisected and glued to a specimen
mounting block and submerged in oxygenated, ice-cold ACSF. Brains were then
sectioned coronally into ~400 µm slices using a Vibratome® 1000 (Leica Biosystems,
Buffalo Grove, IL) and transferred to a custom interface holding chamber (Mathis et al.,
2011) and incubated with warmed (32° C) oxygenated ACSF containing 2 mM CaCl2
until electrophysiological recordings (usually 1.5-5 h).
Slices were transferred to a Kerr Tissue Recording system (Kerr Scientific Instruments,
Christchurch, New Zealand) and submerged in warmed (~32° C) oxygenated ACSF
containing 2mM CaCl2 and 2mM MgSO4. Schaffer collaterals were activated with a
bipolar stainless steel electrode located in stratum radiatum. Stimulus intensity was
controlled by a constant current stimulus isolation unit (World Precision Instruments,
Sarasota, FL), and stimulus timing was controlled by LabChart 8 software
(ADInstruments Inc., Colorado Springs, CO). Field potentials were recorded in CA1
stratum radiatum using a Ag/AgCl wire located ~1-2 mm from the stimulating electrode.
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Field potentials were amplified 100X and digitized at 10kHz using the Kerr Tissue
Recording System amplifier and a 4/35 PowerLab analog-to-digital converter
(ADInstruments). To assess basal synaptic strength, 100 µs stimulus pulses were given
at 12 intensity levels (range 25–500 µA) at a rate of 0.1 Hz. Five field potentials at each
level were averaged, and measurements of fiber volley (FV) amplitude (in mV) and
excitatory postsynaptic potential (EPSP) slope (mV/ms) were performed offline using
LabChart 8 software. Synaptic strength curves were constructed by plotting EPSP slope
values against FV amplitudes for each stimulus level. Curves were fit with a three
parameter sigmoidal equation using SigmaPlot 12 software (Systat Software Inc. San
Jose, CA) (Norris et al., 2016). Curve parameters included maximal EPSP amplitude
(Max), curve slope, and the FV amplitude associated with the half-maximal EPSP
amplitude (half-Max). Maximal synaptic strength for each slice was also estimated by
taking the maximal EPSP slope amplitude during the input/output curve and dividing by
the corresponding FV amplitude. To estimate population spike (PS) threshold, the
EPSP slope amplitude at which a population spike first appeared in the ascending phase
of the field potential was calculated and averaged across five successive trials at the
spike threshold stimulation level.

2.2.11 Statistics. For slice electrophysiology studies, one to three slices from each
hemisphere (either the Gfa104-DsRed or the Gfa104-ΔCN-treated hemisphere) were
analyzed. Synaptic measures were averaged across all slices within each hemisphere
and these averaged values were compared across hemispheres using paired T-tests,
with significance set at p < 0.05.
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2.3 Results
2.3.1 Custom antibody shows greater selectivity to a ΔCN fragment. The CN A
subunit is a 521 amino acid protein consisting of a catalytic domain and an autoinhibitory
domain (AID), as well as binding sites for the CN B regulatory subunit and
Ca2+/calmodulin (Ca2+/CaM) (Hashimoto et al., 1990; Kincaid et al., 1990, see Figure 1).
Proteolysis of CN A near the carboxy-terminus by calpains results in the disruption or
removal of the AID leading to reduced Ca2+ sensitivity and constitutive phosphatase
activity (Wu et al., 2004). Calpain-mediated generation of 45 and 48 kDa ∆CN
fragments are found at elevated levels in human brain tissue during cognitive decline,
are triggered by oligomeric Aβ, and are causatively linked to greater CN signaling and
neurodegeneration (Wu et al., 2004; Abdul et al., 2011).
CN A antibodies that target epitopes between amino acid residues 425 and 521 (i.e. C
terminus antibodies) recognize full length CN (FL-CN), but do not detect ΔCN fragments
and may therefore fail to identify important pathological changes in CN regulation. In
contrast, N terminus-directed antibodies identify CN proteolysis in Western blot
applications, but do not distinguish between FL-CN and ΔCN in immunohistochemical
applications, making it difficult to pinpoint where CN proteolysis occurs in a
heterogeneous cell population. We therefore set out to make new antibody reagents with
greater selectivity to ΔCN, relative to FL-CN. Peptides composed of amino acids found
immediately upstream of calpain-dependent cleavage sites (Wu et al., 2004) were used
to immunize rabbits (Figure 2.1). Antisera generated by immunization with the ESVLTLK
peptide, found immediately upstream from lysine 424, revealed a 45-48 kDa band in
preliminary Western blots (not shown) and was therefore subjected to further affinity
purification (see Methods) to obtain ∆CN antibodies (Figure 2.1A,B). We then performed
Western blots (Figure 2.1C) on whole cell lysates obtained from rat primary mixed
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(neurons + glia) hippocampal cultures exposed to oligomeric Aβ peptides (65 nM for 24
h) to stimulate CN proteolysis, as described in our earlier work (Abdul et al., 2011). The
same samples were processed in parallel for Western blot using a commercially
available N terminus CN antibody for comparison. Both antibodies showed diffuse
labeling in the 70-75 kDa range. However, unlike the ∆CN antibody, the N terminus
antibody showed a prominent band in the 60 kDa range (where FL-CN is found) in
untreated cultures, along with lower molecular weight bands between 25 and 37 kDa
(Figure 2.1C, lane 5). Both antibodies revealed bands in the 45-48 kDa range when
cultures were treated with oligomeric Aβ (Figure 2.1C, lanes 2 and 6), the appearance of
which was blocked by co-application of the calpain inhibitor, calpeptin (Figure 2.1C,
lanes 3 and 7), but not by the caspase inhibitor Z-YVAD (Figure 2.1C, lanes 4 and 8).
Together, these data demonstrate that, relative to the N-terminus antibody, the ∆CN
antibody shows far greater selectivity to calpain-dependent CN proteolytic products in
the 45-48 kDa range.

2.3.2 Astrocytes in AD brain tissue are labeled intensely with the ΔCN antibody.
Western blot analyses have shown elevated levels of ∆CN in brain homogenates from
human subjects with mild-cognitive impairment (Abdul et al., 2011) or AD (Wu et al.,
2010), relative to age-matched non-demented human subjects. Though CN is primarily
found in neurons, it can also appear at high levels in activated astrocytes during injury
and disease, especially around Aβ deposits (Norris et al., 2005; Celsi et al., 2007; Abdul
et al, 2009). To determine if ΔCN is found in activated astrocytes, we
immunohistochemically (IHC) labeled human postmortem brain sections (encompassing
the amygdala and overlying entorhinal cortex) from subjects with confirmed AD (see
Methods). These brain regions show high levels of CN expression in healthy adult
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animals (Goto et al., 1986; Kuno et al., 1992), and exhibit extensive amyloid and
neurofibrillary tangle pathology during AD (Kromer Vogt et al., 1990). Concurrent with
AD-related pathological changes, these brain regions also show widespread GFAP
labeling indicative of gliosis, or astrocyte activation (Murphy et al., 1992 and see Figure
2.2A).
In IHC applications, the ΔCN antibody provided excellent labeling intensity with low
background (Figure 2.2B-E). With rare exceptions (see arrow in Figure 2.2E), most of
the labeled cells exhibited a clear astrocyte morphology, with thick ramified processes,
characteristic of astrocyte activation (Figure 2.2B, 2.2C). Unlike the GFAP antibody,
which provided labeling across most of the tissue (Figure 2.2A), the ΔCN antibody
generally provided only faint labeling, except for numerous discrete regions
characterized by astrocyte “clusters” (Figure 2.2B and C). Cells within these clusters
showed intense labeling, which appeared throughout the soma and usually throughout
several major processes (Figure 2.2C). Many of the most intensely labeled astrocytes
were in close juxtaposition to blood vessels (Figure 2.2D, arrow). Co-staining with an
antibody to Aβ showed that many ΔCN-positive clusters occurred around extracellular
amyloid plaques (Figure 2.2E), suggesting that the proteolysis of CN in astrocytes is
strongly coupled to amyloid pathology, consistent with previous reports (Wu et al., 2010;
Abdul et al., 2011).
In contrast to the conspicuous labeling patterns shown in human AD tissue, staining with
the ΔCN antibody appeared much less prominent in the amygdala of age-matched
control subjects (Figure 2.7). We also observed sparse labeling when tissue sections
were incubated with the ΔCN antibody alone (i.e. without secondary antibody, Figure
2.7) or with the ΔCN antibody plus ESVLTLK blocking peptide (Figure 2.2F and 2.2G).
These results demonstrate that antibody labeling was specific.
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Finally, to confirm that ΔCN is definitively expressed in astrocytes, AD amygdala
sections were co-labeled with a GFAP antibody and confocal microscopy was used to
assess co-localization. As illustrated in Figures 2.2H-K, GFAP and ΔCN were colocalized in numerous cells. Note, however, that ΔCN was not present in all GFAP
positive cells. For instance, arrowheads in Figures 2.2H-J show two immediately
adjacent astrocytes, with one cell expressing ΔCN and the other cell apparently devoid
of ΔCN (also see Figure 2.2K). These images, along with the immunohistochemical
evidence shown in Figures 2.2B-2.2E highlight the heterogeneous nature of CN
proteolysis in astrocyte populations associated with AD pathology.
As mentioned, a relatively small number of ΔCN-positive cells in the amygdala exhibited
a clear neuronal morphology (see Figure 2.2E, arrow). As a further attempt to explore
neuronal labeling with the ΔCN antibody, we investigated hippocampal sections using
both immunohistochemistry and confocal microscopy. The hippocampus is
advantageous for immunohistochemical investigations because its neurons are densely
packed into discrete layers and are easy to identify, even in unstained tissue. Moreover,
studies from our group have reported signs of hyperactive CN signaling in the
hippocampus during the progression of AD (Abdul et al., 2009; Abdul et al., 2011).
As shown in Figures 2.3A and B, neurons in the CA1 and dentate granule layers of AD
subjects showed abundant expression of the full length form of CN (Goto et al., 1986;
Kuno et al., 1992), as revealed using a commercial antibody to the CN carboxyl
terminus. The ΔCN antibody also labeled neurons, albeit more sparsely (Figure 2.3C
and 2.3D) than the commercial antibody. Similar to amygdala sections, hippocampal
tissue from control subjects provided little to no labeling (Figure 2.7). When present,
ΔCN expression was generally limited to the somal and proximal apical dendritic regions
(for CA1 pyramidal neurons), and tended to be faint, even when other structures in the
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same region, including perivascular elements (Figure 2.3C) and astrocytes (inset, Figure
2.3D), were strongly labeled. In many neurons, ΔCN co-localized with the nuclear
marker, NeuN, which is consistent with earlier work that found elevated levels of
proteolyzed CN in nuclear extracts from AD subjects (Wu et al., 2010). Thus, while
activated astrocytes appear to provide the most striking ΔCN labeling patterns
associated with AD, these cells are not the only source for CN proteolysis.

2.3.3 Association of ΔCN with microinfarcts. In addition to AD, ΔCN fragments have
been observed in a number of other neurodegenerative conditions, particularly those
caused by vasculature disruption and/or occlusion (Shioda et al., 2006; Shioda et al.,
2007; Rosenkranz et al., 2012). Vascular pathology is highly co-morbid with AD
pathology and likely exacerbates cognitive decline with the progression of AD (Kalaria et
al., 2012; van Norden et al., 2012; Raz et al., 2016; Corriveau et al., 2016; Nelson et al.,
2016; Vemuri and Knopman, 2016; Wilcock et al., 2016). Mounting evidence suggests
that microinfarcts are among the most common and insidious contributors to vascular
cognitive impairment and dementia (VCID) (Smith et al., 2012; Kapasi and Schneider,
2016). Moreover, microinfarcts are commonly enveloped by activated astrocytes (Wang
et al., 2012; van Veluw et al., 2015).
To determine whether the appearance of ΔCN coincides with vascular disruption, we
investigated cortical brain sections from subjects with confirmed microinfarct pathology.
Figure 2.4A-E shows ∆CN labeling in SMTG sections from a 90 year old human subject
with multiple microinfarcts, but little-to-no AD pathology (Braak stage II). At low
magnification, several discrete regions show very intense ΔCN labeling (Figure 2.4A).
The region marked by the arrowhead in Figure 2.4A is shown at higher magnification in
an H&E labeled serial section in Figure 2.4B and confirms the presence of a microinfarct
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approximately 400 μm in greatest dimension (approximate center shown with arrow).
This microinfarct is surrounded by numerous cells intensely labeled for ΔCN (Figure
2.4C), many of which exhibit clear activated astrocyte histomorphology (Figures 2.4D-E).
When the ΔCN antibody was delivered in the presence of the ESVLTLK peptide (Figure
2.4F and 2.4G), cellular labeling was greatly diminished, confirming binding specificity.
Interestingly, ΔCN-positive microinfarcts were not labeled with a commercial C-terminusdirected antibody that selectively detects full length CN (Figure 2.4H and I). Note,
however, that the C-terminus antibody does label neurons within the same brain section
(Figure 2.8). Thus, microinfarcts appear to be more strongly associated with proteolyzed
CN than with full-length CN.
Confocal micrographs showed that ΔCN was associated with both activated astrocytes
and neurons in the immediate vicinity of microinfarcts (Figure 2.5). ΔCN localization to
astrocytes was most prominent around the microinfarct core, with expression diminishing
with increasing distance from the injury (Figure 2.5A-2.5D). For neurons, ΔCN was most
highly expressed within the microinfarct core, though many ΔCN/NeuN positive cells
could also be found outside the core as well (Figure 2.5E-H). Together; these
observations demonstrate that CN proteolysis can occur in the immediate vicinity of
small vessel pathology in the human brain.

2.3.4 Forced overexpression of ΔCN in astrocytes of intact rats disrupts synaptic
function. The consequences of CN proteolysis in neurons have been investigated in
many different model systems (Norris, 2014). Conversely, little is known about the
functional outcomes of CN proteolysis in astrocytes. Hyperactivation of CN signaling in
astrocytes has been linked to the elevated expression of inflammatory mediators,
impaired glutamate regulation, Aβ production, and altered astrocytic Ca2+ dynamics
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(Norris et al., 2005; Fernandez et al., 2007; Canellada et al., 2008; Sama et al., 2008;
Jin et al., 2012; Grolla et al., 2013; Norris, 2014). Using adeno-associated virus (AAV)
vectors, equipped with astrocyte specific promoters, we have shown that the selective
inhibition of astrocytic CN/NFAT signaling provides numerous beneficial effects in a
mouse model of AD (Furman et al., 2012), and a rat model of traumatic brain injury
(Furman et al., 2016). These results suggest that hyperactivation of CN in astrocytes can
mediate and/or exacerbate pathophysiological processes.
One of the primary responsibilities of astrocytes is to regulate synaptic transmission and
plasticity (Allen, 2014). Since we previously found that inhibition of astrocytic CN/NFAT
signaling protects multiple synaptic properties, we sought to test whether the presence
of ΔCN in astrocytes is sufficient to drive synaptic dysfunction. AAV2/5 vectors
expressing ΔCN-DsRed2 or DsRed2 alone (control vector) were injected into the
hippocampus of adult rats. One hemisphere received ΔCN and the other hemisphere
received DsRed2 control vector (Figure 2.6A). The ∆CN used here lacks the CN AID, is
nearly identical in size to the ∆CN fragment found in human AD brain (Figures 2.2 and
2.3, and see Furman et al., 2012), and shows increased phosphatase activity when
expressed in many different cell types (Wang et al., 1999; De Windt et al., 2000; Friday
et al., 2000; Norris et al., 2010), including primary astrocytes (Sama et al., 2008). Both
ΔCN and DsRed2 were transcriptionally regulated by a truncated human GFAP
promoter (Gfa104), which provides astrocyte-specific expression (Ortinski et al., 2010;
Cui et al., 2014). Using confocal microscopy and/or immunodepletion assays, we
previously showed that AAV-mediated expression of EGFP was driven exclusively in
astrocytes (in mice and rats) when a similar Gfa2 promoter was used (Furman et al.,
2012; Furman et al., 2016). Consistent with these observations, immunofluorescent
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labeling of the DsRed2 tag in the present study was limited to astrocytes and showed no
co-localization with the neuron-specific protein MAP2b (Figure 2.6B).
At 4 months post-AAV injection, brain slices from both hemispheres were harvested and
processed in parallel for the electrophysiological assessment of basal CA3-CA1synaptic
strength. Field EPSP slopes were recorded in CA1 stratum radiatum and plotted against
corresponding FV amplitudes at 12 different stimulus intensities to generate synaptic
strength curves (Figure 2.6C, D). Compared to slices from the DsRed2 control vectortreated hemisphere, slices from the ∆CN-treated side exhibited depressed synaptic
strength curves (Figure 2.6D) with a corresponding reduction in the maximal EPSP/FV
ratio (p <0.05, Figure 2.6E). Further analyses of synaptic strength curve parameters
revealed a significant reduction in the maximal EPSP amplitude (p <0.05), but did not
find any differences in the slope of the curve or in the FV amplitude necessary for halfmaximal EPSP amplitude (Figure 2.6F). Finally, while the evoked field EPSP was
reduced in slices from the ∆CN-treated hemisphere, these slices were also generally
more excitable as indicated by a reduced population spike (PS) threshold (Figure 2.6G).
A similar reduction in the PS threshold has been reported in APP/PS1 mice (Furman et
al., 2012) and may be indicative of neuronal hyperexcitability. Together, these results
suggest that the presence of ∆CN in astrocytes is sufficient to drive synaptic dysfunction
in intact animals.

2.4 Discussion
CN proteolytic fragments show abnormally high levels of phosphatase activity under
resting Ca2+ levels and are associated with numerous forms of neurologic injury and
disease (Norris, 2014). Using a novel antibody generated to the ΔCN proteolytic
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fragment, the present study has provided some of the first evidence that CN proteolysis
can occur extensively in astrocytes associated with AD and small vessel pathology.
Furthermore, overexpression of the ΔCN fragment in astrocytes of otherwise healthy
adult animals causes synaptic deficits. The results demonstrate that proteolysis may be
an important source of CN dysregulation in astrocytes leading to altered astrocyte
function and neural dysfunction with the progression of neurodegenerative disease.

2.4.1 Importance of antibody selection for assessing CN expression/activity in
disease. The proteolysis of CN was first shown under in vitro conditions, but has
subsequently been demonstrated to occur in intact nervous tissue after cellular insult
(Wu et al., 2004; Huang et al., 2005; Shioda et al., 2006; Shioda et al., 2007; Abdul et
al., 2011; Rosenkranz et al., 2012). Using an antibody directed to the N terminus of CN
A, Wu et al. (2004) showed that at least three distinct CN A fragments are generated in
vivo in response to cellular injury and high levels of calpain activity. The 48 and 45 kDa
fragments generated by calpain-dependent proteolysis are fully-functional enzymes that
show high activity at low (resting) Ca2+ levels due to the absence of an AID that normally
keeps CN activity in check. High levels of CN proteolysis can dramatically alter cellular
function and viability (Wang et al., 1999; Wu et al., 2004; Abdul et al., 2011), which
highlights the importance of choosing the appropriate antibody to investigate CN
functions in CNS injury and disease. In particular, C-terminus directed antibodies to CN
A only detect full length CN and may give the impression that CN expression is reduced,
rather than proteolytically activated, under neurodegenerative conditions. The use of Cterminus antibodies may explain why early reports observed reductions in CN A levels
and activity in AD tissue (Billingsley et al., 1994; Ladner et al., 1996; Lian et al., 2001;
Karch et al., 2013).
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While N-terminus antibodies are useful in Western blot applications for determining the
extent of CN proteolysis in whole brain tissue, they do not specify which cell types give
rise to CN proteolysis, nor do they determine whether proteolysis occurs selectively in
the close proximity of specific pathological markers. Furthermore, because of the vast
cellular heterogeneity of the CNS, changes in proteolysis for any one cell type may be
masked or diluted in biochemical analyses of whole tissue homogenates. This problem
severely limits mechanistic insights into the downstream consequences of CN
proteolysis, primarily because CN is expressed in many different cell types (Goto et al.,
1986; Kuno et al., 1992; Hashimoto et al., 1998; Norris et al., 2005; Celsi et al., 2007;
Abdul et al., 2009), each of which can use CN for unique functions. For example, when
expressed in neurons using gene delivery techniques, ∆CN causes alterations in
synaptic function, Ca2+ channel dysregulation, degeneration of neurites, and apoptosis
(Kromer Vogt et al., 1990; Celsi et al., 2007; Smith et al., 2012; Norris, 2014;
Rojanathammenee et al., 2015; van Veluw et al., 2015; Kapasi and Schneider, 2016).
Astrocytes may also be an important source for CN dysregulation (Furman and Norris,
2014), which is notable given the increasing attention astrocytes have received for their
contributions to neurologic dysfunction during aging, injury, and disease (Hamby and
Sofroniew, 2010; Pekny and Pekna, 2014; Verkhratsky et al., 2012; Verkhratsky et al.,
2015). Overexpression of ∆CN in astrocytes leads to the production and release of a
variety of immune factors (e.g. cytokines and chemokines) linked to glial activation and
neuroinflammation (Norris et al., 2005; Fernandez et al., 2007; Sama et al., 2008). While
many of these cell-specific processes arise in neurodegenerative diseases, and are
blocked by both calpain and CN inhibitors (Norris, 2014), it has been unclear if (and to
what extent) CN proteolysis actually occurs in these cell types during the disease
process.
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The ΔCN antibody was designed with the intent to identify the cellular source for CN
proteolysis in diseased and/or injured brain tissue. This antibody showed much greater
selectivity to calpain-generated CN fragments than to full-length CN (Figure 2.1C) in
Western blot applications and was associated with high-signal to background labeling in
IHC applications (e.g. see Figures 2.2 and 2.4). When incubated with postmortem
human brain sections from confirmed AD cases, the ΔCN antibody provided intense
labeling of astrocyte clusters, many of which were in close juxtaposition to Aβ deposits
and/or blood vessels (Figure 2.2). Previously, we observed a similar co-localization of
CN to activated astrocytes in amyloidogenic mice and human AD brain tissue using Nterminus antibodies, which identify both full length and proteolyzed CN (Norris et al.,
2005; Abdul et al., 2009). The findings of the present study suggest that the elevated
activity of CN and/or CN-dependent signaling mediators (e.g. NFAT) reported earlier for
AD mouse models and human AD cases (Reese et al., 2008; Abdul et al., 2009; Wu et
al., 2010; Abdul et al., 2011) may arise, at least partly, from the calpain-dependent
proteolysis of CN in astrocytes.

2.4.2 ΔCN and Microinfarcts. ΔCN labeling was also particularly intense for astrocytes
in human cases characterized by extensive vascular pathology (Figure 2.4).
Microinfarcts, in particular, are increasingly recognized as a key mechanism for
dementia (Smith et al., 2012; Kapasi and Schneider, 2016). Though etiologically distinct
from AD pathology, microinfarcts and other forms of vascular pathology show high
comorbidity with AD, where they appear to exacerbate neurodegenerative processes
and hasten cognitive decline (Kalaria et al., 2012; van Norden et al., 2012; Raz et al.,
2016; Corriveau et al., 2016; Nelson et al., 2016; Vemuri and Knopman, 2016; Wilcock
et al., 2016). Microinfarcts are often defined by extensive gliosis surrounding the core,
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including profound astrocyte activation (Wang et al., 2012; van Veluw, 2015). Similar to
Aβ plaque-associated astrocytes, we found that activated astrocytes surrounding
microinfarcts were intensely labeled with the ΔCN antibody (Figure 2.4), suggesting that
small vascular pathologies can result in aberrant CN proteolysis, which may, in turn,
contribute to further glial activation and/or elevated levels of harmful neuroinflammatory
factors (Sama et al., 2008). While many of the ΔCN-labeled cells around microinfarcts
had activated astrocyte morphology, it’s possible that GFAP-negative astrocytes,
activated microglia, and/or infiltrating immune cells are also an important source of ΔCN.
Microglia, in particular, express numerous CN-dependent substrates, including NFATs
that play key roles in cytokine production and neuroinflammation (Nagamoto-Combs and
Combs, 2010; Shiratori et al., 2010 Kim et al., 2011; Rosenkranz et al., 2012;
Rojanathammenee et al., 2013). Other cells relevant to the vasculature, such as
microvascular pericytes, can express high levels of NFAT4 (Filosa et al., 2007), which is
intriguing given that ∆CN was also commonly observed in or around microvessels in the
present study.
In addition to glial cells, we also observed ΔCN labeling in neurons, especially within
close proximity to microinfarcts (Figure 2.5B). NeuN- ΔCN colocalization appeared most
extensive within the microinfarct core region, which may be subject to marked hypoxic
damage (Shih et al., 2013)—a well-characterized stimulus for CN proteolysis in brain
tissue (Shioda et al., 2006; Shioda et al., 2007). As mentioned, ΔCN expression in
neurons has been shown to activate both necrotic and apoptotic signaling pathways
(Wang et al., 1999; Wu et al., 2004), suggesting that the neuronal expression of ΔCN
within and near microinfarcts may also be a major contributor to neurodegeneration
associated with vascular damage. Additional work directed at identifying all of the
different cell types expressing ΔCN following microvessel damage and how CN
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proteolysis in each cell type specifically contributes to neural function/dysfunction should
provide important insights into the pathophysiology of AD and VCID.

2.4.3 ∆CN in Astrocytes and synapses. One of the major functions of astrocytes is to
promote the structural and functional integrity of synaptic contacts (Allen, 2014). Deficits
in synaptic function are usually found in animal models characterized by extensive
astrocyte activation (Bachstetter et al., 2012; Furman et al., 2012; Rossi, 2015),
suggesting that activated astrocytes directly damage and/or lose the capacity to protect
synapses. We previously showed that the blockade of astrocytic CN/NFAT signaling,
using AAV-Gfa vectors, ameliorated synaptic deficits in both basal synaptic transmission
and plasticity and normalized the PS threshold in APP/PS1 mice (Furman et al., 2012).
Similar levels of synaptoprotection were observed in brain-injured rats treated with the
same AAV reagents (Furman et al., 2016). Consistent with these findings, the present
study found that hippocampal synaptic strength was compromised in healthy adult rats
following the forced overexpression of ∆CN in astrocytes. Together, the results are
consistent with the possibility that proteolytic activation of CN in activated astrocytes is a
crucial causative mechanism for the deterioration of synaptic function. However, our
results do not rule out the possibility that full-length CN could mediate similar effects (in
the absence of proteolysis), if the phosphatase was activated at high levels by normal
binding to Ca2+/calmodulin.
While the present study did not address how astrocytic CN activity disrupts synaptic
function, there are many possible mechanisms that will need to be systematically
investigated. For instance, CN signaling pathways help drive the production of numerous
immune factors, including tumor necrosis factor and other cytokines, which are
implicated in chronic neuroinflammation (Griffin et al., 1998; Mrak and Griffin, 2005; Van
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Eldik et al., 2007; Sama et al., 2008) and widely regarded as causal factors of synaptic
decline in animal models of aging, injury, and AD (Pickering and O’Connor, 2007; Sama
and Norris, 2013; Rossi, 2015). Synaptic function is also strongly modulated by a variety
of releasable factors (e.g. SPARC/SPARC-L, C3, and ephrin/Eph receptors) (Stevens et
al., 2007; Jones et al., 2011; Murai and Pasquale, 2011), which are produced in
activated astrocytes (Ridet et al., 1997; Frugier et al., 2012; Ingram et al., 2014) and
sensitive to CN/NFAT activity (Norris et al., 2005; Furman et al., 2016), while other
toxins, such as glutamate and Aβ peptides, can be released from activated astrocytes
via the CN-dependent downregulation of glutamate transporters (Sama et al., 2008;
Abdul et al., 2009) and the upregulation of β-secretases (Furman et al., 2012; Jin et al.,
2012) respectively. But, regardless of the specific cellular mechanism, our data provide
proof-of-concept that CN hyperactivity in astrocytes, especially in areas of amyloid and
vascular pathology (as shown with the ∆CN antibody, see Figures 2.2-2.4), can have
deleterious effects on synapses. Whether the proteolysis of CN is directly linked to the
striking synapse loss that occurs with AD (Scheff et al., 2013; Scheff et al., 2015; Scheff
et al., 2016) and VCID (Sinclair et al., 2015) is still unknown and will need to be
determined.

2.4.4 ∆CN in Astrocytes: Deleterious vs Beneficial Effects on Neural Function. The
electrophysiological findings in the present study are consistent with numerous studies
that have found a deleterious role of CN signaling in rodent models of aging (Foster et
al., 2001; Norris et al, 2005), AD (Norris et al., 2005; Kuchibhotla et al., 2008; Reese et
al., 2008; Taglialatela et al., 2009; Wu et al., 2010; Furman et al., 2012; Hudry et al.,
2012; Taglialatela et al., 2015), and injury (Wu et al., 2004; Huang et al., 2005; Shioda et
al., 2006; Shioda et al., 2007; Furman et al., 2016). The data provided here also directly
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supports our previous work (Furman et al., 2012; Furman et al., 2016) and work from
others (Fernandez et al., 2016) showing that astrocyte-specific inhibition of CN signaling
results in improved neuronal viability, synaptoprotection, and/or improved cognition.
However, these results are apparently in disagreement with another study by the TorresAleman lab that showed a number of neurologic benefits in amyloidogenic mice when
∆CN was overexpressed in astrocytes (see Fernandez et al., 2012). The reason(s) for
this discrepancy is not immediately clear. In many tissues, overexpression of ∆CN is
associated with cellular toxicity (e.g. see Wang et al., 1999; Wu et al., 2004). It’s
therefore possible that the overexpression of ∆CN, in the context of an already toxic
environment (i.e. high amyloid levels), leads to the death of activated astrocytes. The
end result may be beneficial, if activated astrocytes are having a deleterious impact on
neural function. Though we observed no evidence for astrocyte deterioration in adult rats
treated with AAV-Gfa vectors, the viability of ∆CN -expressing astrocytes should be
closely monitored in future studies, especially when ∆CN is expressed in animal models
where neuropathology is already extensive. Alternatively, the beneficial vs. detrimental
effects of ∆CN could be a further indication of the highly heterogeneous nature of
astrocytes both within and across different brain regions. In the present study, forced
overexpression of ∆CN was limited to astrocytes in the hippocampus, which is also
where we observed beneficial effects of CN/NFAT inhibition using AAV-Gfa vectors
(Furman et al., 2012; Furman et al., 2016). In contrast, Fernandez et al. 2012 induced
∆CN expression in astrocytes across the entire forebrain. The specific outcome of ∆CN
expression may therefore depend critically on the brain region examined. It’s also
possible that ∆CN generates some neurologic benefits, including improved cognition, at
the cost of other functions, like synaptic transmission and plasticity, though this would be
contrary to numerous other studies where synaptic deficits and cognitive impairments
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run in parallel. Finally, it is interesting to note that a more recent study by the TorresAleman lab (Fernandez et al., 2016) reported a number of functional benefits in AD
transgenic mice following treatment with reagents that disrupt astrocytic CN signaling,
which is more consistent with our present findings and previous research. Regardless, it
would appear that astrocytic CN signaling is highly complex and additional research will
be necessary to fully characterize the molecular, cellular, and behavioral phenotypes of
animals that show elevated levels of ∆CN in brain astrocytes.
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Figure 2.1 Production of ΔCN antibody.
(A) Calpain-dependent cleavage between lysine 424 and glycine 425 generates a 45–48
kDa fragment (ΔCN). (B) The peptide immediately upstream from the ΔCN cleavage site
(ESVLTLK) was used to immunize rabbits. Antisera were column-purified to enrich the
ΔCN antibody. (C)Western blot showing proteolysis of CN in primary rat hippocampal
cultures treated for 24 h with oligomeric Aβ1–42 peptides (65 nM) in the presence or
absence of the CP inhibitor, calpeptin (10 μM) or caspase-1 inhibitor, Z-YVAD. The ΔCN
antibody (left panel) detects the 45–48 kDa fragment but not full-length CN. Commercial
N terminus antibodies (right panel) recognize both full-length (60 kDa) CN and the 45–48
kDa fragment. Blockade of CP activity with calpeptin prevents Aβ-dependent proteolysis
while inhibition of caspase activity does not.
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Figure 2.2 ΔCN antibody labels astrocytes in human tissue.
(A) GFAP labeling in an AD section from a subject with confirmed AD. (B–C) Low and
high power photomicrographs of human AD amygdala showing intense labeling of
astrocyte clusters and (D) astrocytes in close proximity to microvessels using the ΔCN
antibody. (E1–4) Co-labeling reveals that ΔCN-positive cells (brown) appear around
amyloid deposits (blue). Though most cells contained within clusters exhibited a clear
astrocyte morphology, some cells showed neuron-like characteristics (see arrow in E4).
(F, G) Serial sections of amygdala labeled with ΔCN antibody alone (F) or ΔCN antibody
plus ESVLTLK blocking peptide (G). (H–K) Confocal micrographs showing labeling with
a GFAP antibody (red) and the ΔCN antibody (green). The merged image shows areas
of colocalization, indicating that most GFAP-positive astrocytes have regions that are
also occupied by the ΔCN fragment (arrows). However; some GFAP-positive astrocytes
(indicated by arrowheads and shown at larger magnification in K) were devoid of ΔCN.

50

Figure 2.3 ΔCN antibody shows faint labeling in NeuN positive neurons.
(A–B) Photomicrographs of human AD hippocampus in CA1 (A) and in the dentate gyrus
(B) show strong labeling of neurons using a commercial antibody to the C-terminus of
CN. (C–D) Labeling of the CA1 and dentate granule layers with the ΔCN antibody.
Neuronal labeling with the ΔCN antibody was relatively faint and limited to the cell body
region and proximal apical dendrites (for pyramidal neurons). Inset in D shows an
intensely labeled astrocyte and blood vessel near weakly labeled dentate granule cells.
(E–F) Low (E) and higher-powered (F) confocal micrographs of NeuN and ΔCN doublelabeling in area CA1 of an AD subject. Merged low-power images from the region
denoted by the arrow in panel E shows punctate localization of ΔCN (red) to NeuN
positive cell bodies (green).
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Figure 2.4 ΔCN antibody labels microinfarcts.
Representative low magnification photomicrograph (A) that shows ΔCN labeling around
several microinfarcts (arrows and arrowhead) in neocortex. (B) Serial section through
neocortex stained by H&E to confirm the presence of microinfarcts. The image shown is
a high magnification of the region denoted by the arrowhead in Panel A. (C) High power
photomicrograph of the region in A (arrowhead) showing intense ΔCN antibody labeling
of astrocytes. Higher magnification of the areas denoted by arrows are shown in panels
D and E. (F, G) Serial sections of neocortex labeled with ΔCN antibody alone (F) or ΔCN
antibody plus ESVLTLK blocking peptide (G). The blocking peptide greatly reduced the
labeling intensity of the ΔCN antibody. (H, I) Serial sections of human cortical tissue
treated with the ΔCN antibody (H), or a commercial C-terminus antibody (I) that detects
FL-CN, but not proteolyzed CN (G). Little to no labeling in the microinfarct region is
observed with the C-terminus antibody.
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Figure 2.5 ΔCN localizes to astrocytes and neurons around microinfarcts.
(A) Merged confocal micrograph showing the colocalization of ΔCN (green)with GFAP
(red). B–D, high magnification images of the infarct in Panel A shown in individual
channels (B, C) and merged (D). Co-localization of ΔCN with GFAP was most extensive
in the region immediately adjacent to the infarct. (E) Merged confocal micrograph
showing the colocalization of ΔCN (green) with NeuN (red). Note, this image is a serial
section of the region shown in Panel A. F–H, high magnification images of the infarct in
Panel E shown in individual channels (F, G) and merged (H). Co-localization of ΔCN
with NeuN was most extensive in the microinfarct core, but could also be observed for
numerous cells adjacent to the insult.
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Figure 2.6 ΔCN expression and hippocampal synaptic function.
(A) AAV2/5 vectors encoding a DsRed2 control construct or a ΔCN construct under the
control of the astrocyte-specific promoter, Gfa104, were injected into alternate
hemispheres (intrahippocampal) of intact adult rats (n = 6). B, Confocal micrograph of
the stratum radiatum region of area CA1 showing MAP2b (green), GFAP (blue), and
DsRed2 (red). Arrow points to a DsRed2-positive astrocyte shown in higher
magnification images below. While many astrocytes labeled positive for DsRed2, there
was no overlap in labeling for DsRed2 and MAP2b. C, representative waveforms
recorded in stratum radiatum of CA1 in response to electrical orthodromic stimulation of
Schaffer collaterals illustrating a reduced EPSP in slices from the ΔCN-treated
hemisphere relative to the DsRed2-treated hemisphere, given a similar FV amplitude.
Calibration bars: vertical 0.5 mV; horizontal 5 msec. D, Synaptic strength curves
showing the mean ± SEM EPSP slope values plotted against the mean ± SEM FV
amplitude values at increasing stimulus intensities. The average synaptic strength curve
for the ΔCN-treated hemisphere exhibited a downward shift, consistent with reduced
basal synaptic strength. E, Mean ± SEM maximal EPSP-to-FV ratio in each AAV-treated
hemisphere. F, Synaptic strength curve parameters (Mean ± SEM maximal EPSP, curve
slope, and half-maximal activation) from the data shown in panel C. G, Mean ± SEM PS
threshold in ΔCN- and DsRed2-treated slices. *p b 0.05, paired t-test.
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Figure 2.7 ΔCN labeling controls.
Labeling with the ΔCN antibody in both amygdala (far left column) and hippocampus (far
right column) from non-demented control subjects reveals little-to-no labeling across the
sections. Furthermore, sections were labeled in the absence of primary antibody and
secondary antibody as additional controls to confirm antibody specificity.
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Figure 2.8 Commercial C-terminus CN antibody reveals labeling of neurons.
A cortical section labeled with a commercial C-terminus CN antibody reveals labeling of
neurons.
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3.1 Introduction
Astrocytes are one of the most abundant cell types in the brain (Chen and Swanson,
2003), and play a vital role in maintaining healthy nervous tissue. Calcineurin (CN), an
exquisitely Ca2+-sensitive Ser/Thr protein phosphatase, is profuse in neurons under
normal conditions (Klee, 1991) but with neurodegenerative diseases (e.g. Alzheimer’s
disease and vascular cognitive impairment and dementia) CN can be highly expressed
in a subset of activated astrocytes (Hashimoto et al., 1998; Norris et al., 2005; Celsi et
al., 2007; Abdul et al., 2009). Activated astrocytes exhibit an increased production of
pro-inflammatory cytokines, a decreased production of glutamate transporters, and a
hypertrophic morphological change, and they have been implicated as a major
component of neuroinflammation (Sama et al., 2008; Fuller et al., 2009; Sofroniew,
2009; Fuller et al., 2010; Sofroniew and Vinters, 2010).
Work from our lab and others has shown that changes in signaling pathways in
activated astrocytes-- including CN signaling pathways-- can contribute to neural
dysfunction (Abdul et al., 2009). One pathway in particular, the CN/nuclear factor of
activated t-cells (NFAT) pathway, has been implicated in the initiation and/or progression
of Alzheimer’s disease (AD) (Abdul et al., 2009; Abdul et al., 2010; Wu et al., 2010;
Hudry et al., 2012). Moreover, inhibition of the CN/NFAT pathway using a small
inhibitory peptide (VIVIT) ameliorates synaptic deficits and glial activation in a mouse
model of AD (Furman et al. 2012). To our knowledge, however, inhibition of CN/NFAT
signaling has not been well-studied in the context of vascular cognitive impairment and
dementia (VCID).
Pathological features of VCID include but are not limited to macro- and microinfarctions, micro-hemorrhages, and arteriolosclerosis (Kapasi and Schneider, 2016).
Buildup of homocysteine, a non-essential amino acid that is a transient, intermediate
step in the transsulfuration pathway, either by genetic mutation (e.g. cystathionine β59

synthase) or dietary modifications (e.g. a deficiency of folate or excess of methionine)
can result in an accumulation of homocysteine known as HHcy (Stipanuk and Ueki,
2011). HHcy is a risk factor not only for cardiovascular conditions (i.e. atherosclerosis
and stroke) (Graham et al., 1997), but it is also an independent risk factor for AD
(Seshadri et al., ,2002) and VCID (Brattstrom et al., 1984). In this study, we used a
Teklad custom research diet (Harlan Laboratories) that was deficient in folate, B6, and
B12, and also had excess methionine (7.7 g/kg) versus control diet (3.0 g/kg) in order to
induce a moderate HHcy (as described by Ernest et al., 2005). Levels of other vitamins
and minerals, as well as protein (195 g/kg) were uniform across the HHcy and control
diets. A previous study using this diet to induce HHcy revealed significant cognitive
deficits on the radial arm water maze, increased number of microhemorrhages, and
increased expression of proinflammatory cytokines after just 11 weeks on the diet
(Sudduth et al., 2013b).
To determine the role of astrocytic CN/NFAT signaling in HHcy-dependent VCID,
we directed expression of a potent NFAT inhibitor, VIVIT, to wild type mice treated with
either control or HHcy diet using adeno-associated virus (AAV) with an astrocyte-specific
promoter. Results revealed that NFAT-DNA binding activity was greater in HHcy mice
compared to mice on control diet. Moreover, consistent with our previous work (Furman
et al., 2016), very preliminary NFAT4 labeling in HHcy tissue exhibited an astrocyte bias.
Treatment of HHcy mice with AAV-Gfa2-VIVIT to inhibit astrocytic NFAT activity
ameliorated deficits in synaptic strength and plasticity. Furthermore, VIVIT had
favorable effects on cerebral blood flow (CBF) and several critical brain metabolites.
Taken together, results suggest that inhibition of CN/NFAT in astrocytes is
synaptoprotective in a mouse model of VCID.
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3.2 Methods
3.2.1 Animals. Female C57Bl/6 (10 weeks of age) were housed in groups, provided
access to food and water ad libitum, and used in accordance with International Animal
Care and Use Committee of University of Kentucky.

3.2.2 Stereotaxic surgery. Mice underwent surgery as previously described (Furman et
al., 2012). Briefly, mice were anesthetized with 2.5% isoflurane throughout the duration
of the surgery. Once immobilized in the stereotaxic frame, AAV vectors (Gfa2-VIVIT or
Gfa2-EGFP) were delivered bilaterally into the hippocampus (4uL/hemisphere) at a rate
of 0.2uL/min using a sterotaxic injector (Stoelting). Coordinates for injection relative to
bregma were +2.0 mm anteroposterior, ±1.5 mm mediolateral, and -1.5 mm
dorsoventral.

3.2.3 Diet. One week post-AAV injection, mice were switched from normal chow diet to a
custom research diet. Mice either went onto control diet (Harlan Teklad 5001 C) or HHcy
diet (deficient in folate, B6, B12; enriched in methionine) (Harlan Teklad TD97345). Mice
were maintained on custom diets ad libitum for a minimum of 11 weeks up to
euthanasia.

3.2.4 Hippocampal slice preparation. Briefly, mice were deeply anesthetized with CO2
and decapitated. Brains were removed and stored briefly in Ca2+-free, ice-cold,
oxygenated (95% O2, 5% CO2) artificial CSF (ACSF) containing the following (in mM):
124 NaCl, 2 KCl, 1.25 KH2PO4, 2 MgSO4, 26 NaHCO3, and 10 dextrose, pH 7.4. 400µmthick sections from one hemisphere were cut on a vibrating microtome (Leica). Slices
were then quickly transferred to netting in a custom Plexiglas holding chamber and
maintained in CaCl2-containing (2 mM) ACSF at an interface with warm (32°C),
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humidified air. Slices were permitted to equilibrate for at least 1.5 h before beginning
electrophysiological analysis.

3.2.5 Synaptic strength and LTP measurements. For each slice, dual-stimulus pulses
(S1 and S2), separated by 50 ms, were delivered at eleven different intensity levels
(range of 25 –500 mA) at a rate of 0.1 Hz to establish a synaptic strength curve. Three
field potentials at each stimulus level were averaged and measurements of fiber volley
(FV) amplitude (in millivolts) and EPSP slope (millivolts per milliseconds) were
performed offline using Clampfit software (Molecular Devices). Averaged EPSP slope
measures were plotted against their corresponding FV amplitudes to estimate the
strength of CA3–CA1 synaptic contacts. Paired-pulse facilitation (PPF) of the EPSP
slope was calculated along the linear portion of the synaptic strength curve by dividing
the EPSP slope of S1 by the EPSP slope of S2 and multiplying by 100. Following
measurements of synaptic strength, stimulation intensity was readjusted to elicit an
EPSP of 1 mV, and stimulus pulses were delivered at 0.033 Hz until a stable 20 min
baseline was established. High-frequency stimulation (two 100 Hz trains, 1 s each, 10 s
intertrain interval) was then delivered at the baseline stimulation intensity to induce longterm potentiation (LTP), followed by an additional 60 min baseline. Within each group,
EPSP slope measures from the last 10 min of the post-LTP baseline were averaged
across slices within animal and compared with the pre-LTP baseline slope average. For
each animal, electrophysiological parameters were averaged across all slices within
each animal (one to three slices), and the n used for statistical comparisons reflects the
number of animals per diet and treatment group. All electrophysiological recordings were
conducted and analyzed by personnel who were blind to diet and treatment conditions.
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3.2.6 Cerebral blood flow and magnetic resonance spectroscopy. MRI experiments
were performed on a 7T Clinscan MR scanner (Siemens) at the Magnetic Resonance
Imaging & Spectroscopy Center of the University of Kentucky. Mice were anesthetized
with 4.0% isoflurane for induction and then maintained in a 1%–2.5% isoflurane and air
mixture using a nose cone. Heart rate (90–110 bpm), respiration rate (50–80
breaths/min), and rectal temperature (36±1 °C) were continuously monitored. A water
bath with circulating water at 50–55 °C was placed outside the room and used to
maintain body temperature.
Cerebral blood flow (CBF) was measured using a pseudocontinuous arterial spin
labeling technique. Paired images were acquired with field of view (FOV) = 40×30mm2,
matrix = 128×128, slice thickness = 1mm, slice = 4, 120 measurements, labeling
duration = 2,100ms, repetition time (TR) = 4,000ms, and echo time (TE) = 20ms.
Quantitative CBF (mL/g/min) was computed employing codes written in Matlab.
Following CBF measurements, we acquired proton (1H) MR spectra (MRS) to determine
brain metabolite levels. In vivo 1H-MRS were obtained using a point-resolved
spectroscopy sequence. Water-suppressed spectra were acquired with following
parameters: TR = 1,500ms, TE = 135ms, spectral width = 60 Hz and average = 400. A
voxel of interest of 18.2mm3(2.0×7.0×1.3mm) covered bilateral hippocampus. An
acquisition of nonwater suppressed spectrum with 10 averages was followed (the rest of
the parameters were kept the same). Both with- and without-water suppression spectra
were then processed using LCModel to determine the concentrations of the metabolites.
LCModel uses a linear combination of model spectra of metabolite solutions in vitro to
analyze the major resonances of in vivo spectra as previously reported (Provencher,
1993). The protocol, including MRI and MRS, took approximately 60 minutes for each
mouse.
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3.2.7 Radial arm water maze. Behavior testing was performed at the University of
Kentucky Rodent Behavior Core. The 2-day radial arm water maze (RAWM) protocol
was carried out as previously described in Alamed et al., 2006. Briefly, a six-arm maze
was submerged in a pool of water maintained at 20.5°C, and a platform was placed at
the end of one arm (equipment and tracking software from Noldus Information
Technology). Each mouse was subjected to 15 trials per day for 2 days. Each mouse
began each trial in a different arm while the arm containing the platform remained the
same. The number of errors (incorrect arm entries) and time to platform was counted
over a 1-minute period. The errors were averaged over three trials, resulting in ten
blocks for the 2-day period.

3.2.8 Electrophoretic mobility shift assay. EMSAs were performed to determine
NFAT-DNA binding as described previously in Furman et al., 2016. Briefly, whole cell
extracts from frozen cortical brain tissue were made using a kit from Active Motif
following the manufacturer’s instructions. Images were obtained and fluorescent bands
were quantified using the Licor Odyssey scanner. Control diet and HHcy tissue samples
were run on the same gel for direct statistical comparisons.

3.2.9 Immunofluorescence. Immunofluorescent labeling was performed as described
previously (Furman et al., 2016; Pleiss et al., 2016). In brief, human cortical samples
were labeled using a 1:20 dilution of anti-mouse NFAT4 (Santa Cruz), amplified and
labeled using tyramide-Alexa 594 from a tyramide signal amplification kit (Invitrogen).
Sections were further labeled using a 1:100 dilution of anti-rat GFAP (Life Technologies)
and labeled using the secondary rabbit anti-rat Alexa 488 (Invitrogen). Images were
obtained using confocal microscopy (Nikon Eclipse Ti).
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3.2.10 Immunohistochemistry. Immunohistochemistry was performed as described
previously (Pleiss et al., 2016). In brief, human cortical sections were labeled primarily
with a 1:25 dilution of ΔCN (custom, see Chapter II) or 1:20 dilution of NFAT4 (Santa
Cruz). Following primary antibody incubation, secondary antibodies and ABC kits
(Vector Laboratories) were used to amplify the signal, followed by detection with DAB
substrate kit (Vector Laboratories). Images were obtained using X scope.

3.2.11 Statistics. Unless otherwise noted, outcome measures were assessed for both
the control diet and HHcy diet animals and compared across treatment groups using
two-way ANOVA. When appropriate, Fisher’s protected least significant difference test
was used for post hoc analyses. Significance for all statistical comparisons was set at p
≤ 0.05.

3.3 Results
3.3.1 Elevated NFAT4-DNA binding and labeling is seen in mouse and human
tissue with vascular-associated pathologies.
We have previously shown that NFAT-DNA binding is elevated in a rat model of TBI, and
the NFAT4 isoform in particular exhibits a strong astrocyte bias (Furman et al., 2016).
Consistent with previous findings, using electrophoretic mobility shift assays (EMSAs)
we found that NFAT-DNA binding was increased cortical tissue from mice on an HHcydiet induced model of VCID compared to tissue from mice on the control diet (Fig 3.1AB). Previous studies have observed ΔCN fragments in neurodegenerative conditions
with significant vascular contributions (Shioda et al., 2006; Shioda et al., 2007;
Rosenkranz et al., 2012). Moreover, elevated NFAT levels have been implicated in
neurodegenerative conditions like MCI (Abdul et al., 2009). Using human cortical tissue
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from a case of VCID with confirmed microinfarct pathology, we found intense labeling of
ΔCN (See Chapter II, Fig 2.4) as well as NFAT4 (Fig 3.1 C, E, F) surrounding the
microinfarct core. Studies have recently, suggested that microinfarcts are the most
common and significant contributor to vascular cognitive impairment and dementia
(Smith et al., 2012; Kapasi and Schneider, 2016). Moreover, activated astrocytes often
envelope the microinfarct core (Wang et al., 2012; van Veluw et al., 2015). Double
labeling with NFAT4 and GFAP, an intermediate filament that is found almost exclusively
in astrocytes (Eng, 1985), revealed co-labeling in human cortical tissue from a confirmed
case of VCID (Fig 3.1 F). Together, these results suggest that CN/NFAT4 signaling is
elevated in astrocytes in both human and mouse tissue with cerebrovascular-associated
pathologies.

3.3.2 Inhibition of CN/NFAT using AAV-Gfa2-VIVIT improves synaptic strength and
plasticity in an HHcy diet-induced model of VCID.
Previous studies have shown that selective inhibition of CN/NFAT in models of AD
(Furman et al., 2012) and TBI (Furman et al., 2016) using adeno-associated virus (AAV)
with an astrocyte-specific promoter (Gfa2) has many protective benefits including
improved synaptic parameters. Moreover, astrocytes play a major role in the regulation
and maintenance of synaptic transmission and plasticity (Allen, 2014). Together, this
suggests that elevated CN/NFAT signaling in astrocytes can significantly contribute to
disease pathophysiological processes and selective inhibition of CN/NFAT provides
many benefits. To our knowledge the role CN/NFAT signaling in a mouse model of VCID
has not been well-investigated.
To determine if selective inhibition of CN/NFAT could improve synaptic parameters in a
diet-induced model of VCID, we delivered AAV 2/5 vectors expressing VIVIT-EGFP or
EGFP alone (control) into the hippocampus of 10 week old C57BL/6 mice. VIVIT has
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been previously shown to potently and selectively inhibit CN/NFAT interactions
(Aramburu et al., 1999). One hippocampus received VIVIT-EGFP and the other
hippocampus received EGFP control for a within-subject experimental design (see Fig
3.2). Both VIVIT-EGFP and EGFP control vectors were transcriptionally regulated by a
human GFAP promoter (Gfa2) which provides astrocyte-specific expression (Lee et al.,
2008), which we have previously shown drives AAV-mediated expression of EGFP
exclusively in astrocytes in both mice and rats (Furman et al., 2012; Furman et al.,
2016).
At 12 weeks post-injection, brain slices from both hemispheres were harvested and
processed in parallel for the electrophysiological assessment of basal CA3-CA1synaptic
strength. Field EPSP slopes were recorded in CA1 stratum radiatum and plotted against
corresponding FV amplitudes at 12 different stimulus intensities to generate synaptic
strength curves. Compared to slices from the EGFP alone control vector-treated
hemisphere, slices from the VIVIT-treated side exhibited improved synaptic strength
curves (Figure 3.3A). Furthermore, following a 20 minute baseline recording, highfrequency stimulation was then delivered at the baseline stimulation intensity to induce
long-term potentiation (LTP), followed by an additional 60 min baseline recording.
Comparted to slices from the EGFP alone control vector-treated hemisphere, slices from
the VIVIT-treated side exhibited improved LTP (Figure 3.3B) Together, these results
suggest that selective inhibition of CN/NFAT signaling in astrocytes is sufficient improve
synaptic parameters and plasticity in an animal model of VCID.
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3.3.3 Inhibition of CN/NFAT using AAV-Gfa2-VIVIT favorably improves cerebral
blood flow and brain metabolite levels in an HHcy diet-induced model of VCID.
Previous studies have shown significant deficits in cerebral blood flow (CBF) in mice on
an HHcy diet versus mice on control diet. Decreased CBF has been associated with
increased vascular risk factors (e.g. hypertension) (Muller et al., 2012; Bangen et al.,
2014). Moreover, changes in several brain metabolites has been implicated in
neurodegenerative conditions such as AD. Specifically, in healthy tissue, levels of Nacetylaspartate (NAA) are normally elevated with reductions in NAA levels being
indicative of increased neuronal loss. Additionally, levels of myo-Inositol (mI) are
normally low but indicate increased glial activation when elevated (Parnetti et al., 1997;
Zhu et al., 2006; Chang et al., 2013; Lin and Rothman, 2014; Lin et al., 2016). To our
knowledge, selective inhibition of CN/NFAT to observe its effects on CBF and brain
metabolite levels has not been well-investigated.
At 14 weeks post-initiation of HHcy diet, we performed arterial spin labeling (ASL)
magnetic resonance imaging (MRI) to measure CBF. We also used magnetic resonance
spectroscopy (MRS) normalized to a water peak to obtain brain metabolite levels (see
Fig 3.2). In mice on the HHcy diet, we found that treatment with AAV-Gfa2-VIVIT
compared to treatment with AAV-Gfa2-EGFP control improved CBF (p = 0.045 [1-tailed
T-test]) (Fig 3.4A). Moreover, treatment with AAV-Gfa2-VIVT compared to treatment with
AAV-Gfa2-EGFP control favorably elevated levels of NAA (p = 0.03 [1-tailed T-test]) (Fig
3.4B) and appeared to favorably reduce levels of mI (n.s) (Fig 3.4C). Although a large
spectrum of metabolites was obtained, we did not see any significant change in other
metabolite levels (e.g. glutamate) in VIVIT-treated versus EGFP control-treated mice on
the HHcy diet. Together, these results suggest that selective inhibition of CN/NFAT in
mice on an HHcy diet favorably improves both CBF and levels of brain metabolites.
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3.3.4 Inhibition of CN/NFAT using AAV-Gfa2-VIVIT did not significantly improve
performance on the radial arm water maze.
The 2-day radial arm water maze (RAWM) task can expose deficits in spatial learning
and memory as described by Alamed et al., 2006. Previous studies have revealed a
significant deficit on the RAWM with mice on the HHcy diet versus mice on a control diet
(Sudduth et al. 2013b). Additionally, inhibition of CN/NFAT signaling in an aggressive
5xFAD model of AD shows improved performance on the RAWM (Sompol et al., in
preparation). To our knowledge, selective inhibition of CN/NFAT and its effect on spatial
learning has not been well-studied in a mouse model of VCID.
At 16 weeks post-initiation of HHcy diet, mice were run on the 2-day RAWM task (see
Fig 3.2). We observed a significant deficit on the task in mice on HHcy diet versus those
on the control diet (Fig 3.5). Within mice on HHcy diet, treatment with AAV-Gfa2-VIVIT
(Fig 3.5, green line) did not significantly improve performance on the task compared to
treatment with AAV-Gfa2-EGFP (Fig 3.5, red line). While results did not show a
significant improvement, treatment with AAV-Gfa2-VIVIT may improve performance on
an executive function task, which tends to be more impaired in VCID as opposed to
learning and memory in AD, and will be elaborated in the Chapter III discussion.

3.4 Discussion
An overarching hallmark of neurodegeneration is neuroinflammation that is driven in part
by CN/NFAT signaling (Griffin et al. 1998; Mrak and Griffin, 2005a). Inhibition of this
pathway has been shown to be beneficial in several mouse models of injury and
neurodegenerative disease (Furman et al., 2012; Furman et al., 2016). Using a potent
NFAT inhibitor specifically targeted to astrocytes, AAV-Gfa2-VIVIT, the present study
has provided some of the first evidence that inhibition of CN/NFAT interactions in a dietinduced mouse model of VCID is synaptoprotective. Moreover, blockade of CN/NFAT
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appears to improve parameters of cerebral blood flow and brain metabolism. The results
suggest that elevated CN/NFAT signaling may contribute to detrimental alterations in
synaptic and cerebrovascular function in VCID, and inhibition of this pathway may have
potential therapeutic benefits.

3.4.1 Elevations in NFAT4 in tissue with vascular pathology: a good target?
The biochemical findings in this study are consistent with previous studies that show
elevated levels of NFATs in tissue following injury and disease (Serrano-Perez et al.,
2011; Neria et al., 2013; Yan et al., 2014; Furman et al., 2016). Our previous work has
found elevated levels of NFAT1 activation in human hippocampus in the early stages of
AD (Abdul et al., 2009) Furthermore, our group recently found elevated levels of NFAT4DNA binding activity in the hippocampus of traumatic brain injured rats that was
confirmed using immunofluorescence and confocal microscopy (Furman et al., 2016).
Consistent with these reports, the present study found elevated NFAT-DNA binding in
cortical tissue from mice on HHcy diet versus those on control diet. Moreover, using
immunohistochemical techniques in human tissue from confirmed cases of VCID, we
found elevated labeling of ΔCN (see Chapter II, also see Fig 2.4) and NFAT4, especially
around microinfarcts (Fig 3.1 C, E, F). The elevations in both CN (see Chapter II) and
NFAT4 suggest that these proteins may be playing a significant role in HHcy-induced
VCID.
What is the role of NFATs and why do we see elevations with CNS injury and
disease? NFATs are transcription factors that are activated by CN in response to Ca2+
influx into cells, and are intimately involved in the immune/inflammatory response
(Crabtree and Olson, 2002). Once in the nucleus, NFATs coordinate the transcription of
pro-inflammatory cytokines and chemokines such as TNFα or IFNγ (McCaffrey et al.,
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1994; Stankunas et al., 1999; Avni et al., 2002; Palanki, 2002; Kitazawa et al., 2004;
Demuro et al., 2005; White et al., 2005; Shankar et al., 2008) (refer to Fig 1.2), which
can have a detrimental effect if chronically activated. Furthermore, we have shown that
both levels of CN and NFATs are robustly elevated in activated astrocytes with CNS
injury and disease (Norris et al., 2005; Furman et al., 2016; Pleiss et al., 2016). Thus, an
ideal therapeutic agent would need to inhibit CN/NFAT interactions specifically in
astrocytes.
Using a potent NFAT inhibitor (VIVIT) targeted directly to astrocytes using a
GFAP promoter (Gfa2) in an adeno-associated virus vector, we have previously shown
that inhibition of CN/NFAT in astrocytes in mouse models of CNS injury and disease is
synaptoprotective (Furman et al., 2012; Furman et al., 2016; Sompol et al., in
preparation), shows cognitive benefits (Furman et al., 2012; Sompol et al., in
preparation), and shows reduced glial activation (Furman et al., 2012). Although AAVGfa2-VIVIT treatment reveals numerous benefits- and AAV vectors in general are
associated with low immunogenicity (Zaiss and Muruve, 2005)- our AAV2/5 constructs
cannot cross the blood-brain barrier (BBB) and therefore must be directly injected into
the brain. Future studies using a less invasive strategy (e.g. AAV9 that can cross the
BBB; Manfredsson et al., 2009) should be considered. However, from a translational
viewpoint, when looking at the benefits of specific CN/NFAT inhibition versus the cost of
invasiveness, AAV-Gfa2-VIVIT should not be ruled out as a viable therapeutic agent.

3.4.2 Astrocytic CN/NFAT and synapses
Astrocytes play a critical role in maintaining the structural and functional integrity of
synapses (Allen, 2014). Animal models characterized by extensive astrocyte activation
often have deficits in synaptic function (Bachstetter et al., 2012; Rossi, 2015),
suggesting that activated astrocytes lose the ability to protect and/or directly disrupt
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synapses. We have previously shown that inhibition of astrocytic CN/NFAT in APP/PS1
mice (Furman et al., 2012), 5xFAD mice (Sompol et al., in preparation), and rats with
traumatic brain injury (TBI) (Furman et al., 2016) ameliorates deficits in basal synaptic
transmission as well as plasticity. Consistent with these findings, the present study found
that hippocampal synaptic strength and plasticity was normalized in mice on an HHcy
diet treated with AAV-Gfa2-VIVIT versus those treated with AAV-Gfa2-EGFP control (Fig
3.3). These results are consistent with the idea that CN/NFAT activation in astrocytes
can help drive synaptic deficits, and inhibition of this pathway can ameliorate these
deficits.
While the results revealed striking synaptoprotection in a mouse model of VCID,
it did not address the mechanisms by which the synaptic deficits occur. One possible
mechanism is the CN-dependent production of numerous immune factors (e.g. TNFα or
IL-6) that are associated with neuroinflammation (Griffin et al., 1998; Mrak and Griffin,
2005a; Van Eldik et al., 2007; Sama et al., 2008) and implicated as causal factors of
synaptic decline in models of CNS injury and disease (Pickering and O’Connor, 2007;
Sama and Norris, 2013; Rossi, 2015). Alternatively, pathogenic toxins associated with
neurodegenerative diseases (e.g. Aβ peptides and glutamate) can be released from
activated astrocytes by upregulation of β-secretases (Furman et al., 2012; Jin et al.,
2012) or downregulation of glutamate transporters (Sama et al., 2008; Abdul et al.,
2009). Regardless of mechanism, this study in combination with our previous studies
shows that astrocytic-specific inhibition of CN/NFAT provides overarching
synaptoprotection in animal models of CNS injury and disease.

3.4.3 Astrocytic CN/NFAT and cerebral blood flow and metabolism
Maintenance of cerebral blood flow is critical for delivering crucial oxygen to brain tissue
(Cipolla, 2009) This may be mediated, in part, by astrocyte endfeet that project onto
72

cerebral blood vessels and participate in regulation of blood flow via release of
vasoactive metabolites (Howarth, 2014; MacVicar and Newman, 2015). Under
conditions of injury and disease, increased astrocyte activation- driven in part by
CN/NFAT activation- disrupts normal astrocyte physiology and may lead to
compromised cerebral blood flow (CBF) which can have detrimental effects on cells.
Previous studies have revealed impairments in cerebral blood flow (cerebral
hypoperfusion) in several neurodegenerative disorders including AD (Lin et al., 2015;
Dai et al., 2016) as well as VCID (Ighodaro et al., 2016; Sun et al., 2016). Consistent
with these findings, the present study revealed a deficit in CBF in mice on an HHcy dietinduced model of VCID that was normalized by treatment with AAV-Gfa2-VIVIT (Fig 3.4).
These results suggest that targeting a mechanism that can help drive astrocyte
activation (i.e. CN/NFAT) may restore normal astrocyte regulation of cerebral vessels
and thus restore CBF.
Additionally, shifts in brain metabolism have been implicated in
neurodegenerative diseases (Herminghaus, 2003; Graff-Radford and Kantarci, 2013).
Metabolites of interest include N-acetylaspartate (NAA), a marker of neuronal viability,
and myo-inositol (mI), a marker of glial activation (Zhu et al., 2006). Previous studies in
both mouse models of neurodegeneration and humans have revealed alterations in
brain metabolites including NAA and mI (Chang et al., 2013; Lin et al., 2015). Consistent
with previous findings, the present study found reduced levels of NAA in mice on the
HHcy diet that was improved by treatment with AAV-Gfa2-VIVIT. Moreover, we found
increased levels of mI in mice on the HHcy diet that was improved by treatment with
AAV-Gfa2-VIVIT (Fig 3.4). Surprisingly, we did not see any significant differences in
levels of glutamate-glutamine.
One possible explanation for the lack of change in glutamate levels could be that
inhibition of CN/NFAT has a stronger effect on brain metabolites associated with
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neuroinflammation (i.e. NAA and mI) than those associated with glutamate
synthesis/release. Additionally, our measurements were done in the hippocampus, but it
would be interesting to determine if significant changes in CBF and/or brain metabolism
occurs in the cortex. Regardless, this study provides proof that astrocyte-specific
inhibition of CN/NFAT can have beneficial effects on cerebral blood flow as well as brain
metabolism.

3.4.4 Spatial memory and VCID: is there a better behavior test?
Consistent with previous studies (Sudduth et al., 2013b) mice on the HHcy diet exhibited
a significant deficit on the radial arm water maze (RAWM) (Fig 3.5). The RAWM consists
of six arms in a round pool, with the platform fixed in the same “goal” arm throughout the
entire paradigm (Alamed et al., 2006) and is designed to elicit impairments in spatial
learning and memory (Shukitt-Hale et al., 2004). Mouse models of AD exhibit striking
deficits in spatial learning and memory (Ashe, 2001; Scearce-Levie, 2011; Yin et al.,
2011). Moreover, we have previously shown that inhibiting CN/NFAT in astrocytes
improves spatial learning and memory in 5xFAD mice treated with the potent NFAT
inhibitor VIVIT versus those treated with our control construct (Sompol et al., in
preparation). However, in the present study, mice on the HHCy diet treated with AAVGfa2-VIVIT did not exhibit a significant improvement in performance on the RAWM
versus those treated with control EGFP (Fig 3.5, green line).
While this is surprising, it is possible that cerebrovascular pathology does not
affect spatial learning and memory in VCID to the same capacity as Aβ plaque and NFT
pathology does in AD. This is plausible because Aβ plaques and NFT accumulate in the
hippocampus in the earliest stages of the disease, and spatial learning and memory is
largely a hippocampal-dependent function. On the other hand, if vascular pathology (e.g.
microinfarcts or microhemorrhages) tends to affect the cortex or other brain regions in
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VCID, perhaps using a treatment targeted to the hippocampus may not be the most
effective strategy. Future studies could explore delivering AAV-Gfa2-VIVIT to astrocytes
in the cortex as opposed to the hippocampus in order to see improvement on the
RAWM. However, if AAV-Gfa2-VIVIT is injected into the cortex, it is likely that protective
effects on hippocampal synaptic function and plasticity will be lost. Alternatively, different
behavioral tests such as the puzzle box or set shifting (Birrell and Brown, 2000;
McAlonan and Brown, 2003; Ben et al., 2011) could be used to elucidate the effects of
CN/NFAT inhibition on executive function. Together, both additional approaches should
help to improve understanding of how inhibition CN/NFAT signaling in VCID affects
behavioral and cognitive performance.
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Figure 3.1 Elevated NFAT4 DNA binding and labeling are seen in mouse and
human tissue with vascular-associated pathology.
(A) Representative gel showing NFAT band (NF) for control [C] and HHcy [H] mouse
cortical tissue. (B) Fluorescence-quantified (AU) NFAT-DNA binding activity for control
tissue vs. HHcy tissue. (C) Photomicrograph of human cortical tissue from confirmed
VCID case reveals intense labeling of NFAT4 surrounding a microinfarct. 10x
photomicrographs of double-labeling with GFAP (D) and NFAT4 (E) reveals co-labeling
(F) between GFAP and NFAT4, and confirms that the NFAT4 isoform has a strong
astrocyte bias.
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Figure 3.2 Experimental design and timeline.
The first cohort of animals was injected bilaterally with both AAV-Gfa2-EGFP (left
hemisphere) and AAV-Gfa2-VIVIT-EGFP (right hemisphere) at 10 weeks of age. One
week post-injection, mice were started on either control diet (n=10) or HHcy diet (n=10).
Mice remained on diet for 11 weeks until sacrifice for slice electrophysiology recordings
(synaptic strength and LTP). A second cohort of mice were injected bilaterally with either
AAV-Gfa2-EGFP (n=20) or AAV-Gfa2-VIVIT-EGFP (n=20) at 10 weeks of age. One
week post-injection, mice were started on either control diet (EGFP, n=10; VIVIT, n=10)
or HHcy diet (EGFP, n=10; VIVIT, n=10). After 14 weeks on the diet, mice were imaged
using MRI to obtain cerebral blood flow (CBF) and metabolite measurements. Two
weeks following MRI measurements, mice underwent radial arm water maze (RAWM)
behavioral testing. Three weeks post-behavior, mice were sacrificed via saline-perfusion.
One hemisphere was immediately snap-frozen at -80°C using liquid nitrogen for
electrophoresis mobility shift assays (EMSAs) and other biochemical measurements; the
other hemisphere was immediately post-fixed in 4% paraformaldehyde and later
sectioned for histochemical measurements.
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Figure 3.3 AAV-Gfa2-VIVIT improves synaptic function in mice on HHcy diet
Synpatic strength curves are shown for mice on control diet (A, left) and HHcy diet (A,
center) in which mean EPSP slope (millivolts per milliseconds) amplitudes (SEM, vertical
error bars) are plotted against FV (millivolts) amplitudes (SEM, horizontal error bars)
across nine stimulus intensity levels. Quantified EPSP/FV ratio (A, right) shows that
VIVIT-treated HHcy mice have normalized synaptic strength relative to control-treated
HHcy mice. Similarly, Gfa2-VIVIT improves LTP in mice on HHcy diet. LTP plots are
shown for mice on control diet (B, left) and HHcy diet (B, center) in which EPSP slope
(% baseline) is plotted against time. Quantified LTP (B, right) revealed that VIVIT-treated
HHcy mice have improved LTP relative to control-treated HHcy mice.
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Figure 3.4 AAV-Gfa2-VIVIT improves CBF/MRS parameters in HHcy mice.
Mice at 25 weeks of age on the HHcy diet treated with EGFP control construct exhibited
a reduction in cerebral blood flow that was improved in mice treated with VIVIT (A). A
reduction in levels of N-acetylaspartate (NAA), indicative of neuronal loss, was seen in
mice treated with EGFP; levels were normalized in mice treated with the VIVIT construct
(B). An increase in levels of myo-inositol (mI), indicative of increased astrocyte
activation, was seen in mice treated with EGFP; levels were normalized in mice treated
with the VIVIT construct (C).
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Figure 3.5 Radial arm water maze behavioral testing did not reveal a significant
improvement in HHcy mice treated with AAV-Gfa2-VIVIT.
Mice were run through radial arm water maze (RAWM) at 27 weeks of age. Analysis by
time (s) revealed a significant deficit in mice on HHcy diet (red and green lines) versus
those on the control diet (blue and black lines). However, analysis by either parameter
did not reveal a significant improvement in mice treated with AAV-Gfa2-VIVIT (green
line) versus those treated with AAV-Gfa2-EGFP (red line).
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4.1 Introduction
Astrocytes are one of the most abundant cell types in the brain and perform
many critical functions in healthy brain tissue (Chen and Swanson, 2003). With aging,
injury, and disease- including neurodegenerative conditions such as Alzheimer’s disease
(AD)- astrocytes become activated which includes a hypertrophic change in morphology,
increased production of pro-inflammatory cytokines, and a decreased regulation of
glutamate transport (Sama et al., 2008; Fuller et al., 2009; Sofroniew, 2009; Fuller et al.,
2010; Sofroniew and Vinters, 2010). Astrocyte activation has been identified as a
profound and key component of neuroinflammation (Colombo and Farina, 2016).
Changes in several signaling pathways in activated astrocytes have been
implicated in neural dysfunction, one of which being the calcineurin (CN) signaling
pathway (Abdul et al., 2009). CN is an exquisitely calcium-sensitive serine/threonine
phosphatase (Klee, 1991), and studies in both human AD tissue and transgenic AD
mouse tissue have revealed intense labeling of CN in activated astrocytes, especially
surrounding amyloid deposits (Norris et al., 2005; Furman et al., 2012; Pleiss et al.,
2016). Astrocytic CN has been shown to mediate many of its effects on neurons and
other cell types via activation of downstream transcription factors, including nuclear
factor of activated T cells (NFAT) and NFκB, both of which have been well-characterized
(Fernandez et al., 2007; Abdul et al., 2009; Abdul et al., 2010). Another potential
downstream target in astrocytes is connexin43 (Cx43), whose interaction with CN has
not been extensively investigated.
Hemichannels (HCs) are composed of connexin protein hexamers (Takeuchi and
Suzumura, 2014; Olsen et al., 2015; Moore and O’Brien, 2015), with Cx43 being the
most abundant isoform in astrocytes (Orellana et al., 2009; Koulakoff et al., 2012;
Orellana et al., 2012). These HCs play a vital role in normal astrocyte function, including
maintenance of synapses and neuronal viability. Studies from our lab and others
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suggest that levels of Cx43 may change during the progression of AD (Nagy et al., 1996;
Mei et al., 2010). The C-terminus of Cx43 is modulated by several protein kinases that
are associated with neuroinflammation e.g. mitogen-activated protein kinase (MAPK)
(Lampe and Lau, 2004; Solan and Lampe, 2009; Solan and Lampe, 2014). A few recent
studies have shown that serine 368 in the C-terminus tail is strongly dependent on CN
activity (Li and Nagy, 2000; Tence et al., 2012). Here, we found that levels of
dephosphorylated connexin43 (dCx43) were increased in human hippocampus in
parallel with CN activity in the mild cognitive impairment (MCI) stage of AD. Similarly,
elevations in dCx43 were observed in rat primary astrocyte cultures treated with the
endogenous inflammatory mediator IL-1β, and this effect was blocked by inhibition of CN
with cyclosporin A (CsA) or by the addition of a decoy mimetic peptide to the C-terminus
of Cx43, 43Gap52. The 43Gap52 peptide did not inhibit NFAT activity, suggesting that the
peptide is relatively selective for Cx43/CN interactions although there was a high amount
of variability between the samples. Lastly, application of CsA or 43Gap52 in primary
astrocyte cultures reduced EtBr uptake in response to IL-1β, suggesting that CN/Cx43
interactions increase astrocytic membrane permeability via HCs under
neuroinflammatory conditions. Together, these results suggest that CN/Cx43
interactions may have a major impact on the function of activated astrocytes and their
maintenance of neural and synaptic function.

4.2 Methods
4.2.1 Human biospecimens. Post-mortem brain samples from the hippocampus were
provided by the Neuropathology Core of the Alzheimer’s Disease Center (ADC) at the
University of Kentucky Sanders-Brown Center on Aging and have been previously
characterized for the status of multiple CN signaling properties including protein levels,
proteolysis, and nuclear localization of NFAT transcription factors (Abdul et al., 2009;
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Mohmmad Abdul et al., 2011). Briefly, specimens from individuals with mild cognitive
impairment (n = 9), with confirmed AD (n = 15), or with low pathology and no dementia
(n = 12) were obtained at autopsy and snap-frozen in liquid nitrogen until use. Diagnostic
criteria have been described in detail elsewhere (Mirra et al., 1991; Nelson et al. 2007;
Hyman et al., 2012; Montine et al., 2012; Nelson et al., 2012). Multiple case descriptors
including age, sex, Braak stage, postmortem autopsy interval, and mini-mental status
are provided for each diagnostic category.

4.2.2 Preparation of cell extracts from human brain tissue. Membrane, cytosolic and
nuclear fractions from hippocampal tissue samples were prepared as described
previously (Abdul et al. 2009). The membrane fractions obtained were resuspended in
sucrose buffer [in mM: 300 sucrose, 75 Nacl, 10 Tris (pH 7.4), 20 EDTA, 20 EGTA]
containing phosphatase, protease, and CP inhibitor cocktails (EMD Chemicals).
Cytosolic and nuclear fractions were resuspended in buffer C [in mM: 50 HEPES (pH
7.6), 50 KCl, 0.1 EDTA, 10% glycerol, 1 dithiothreitol (DTT)], containing phosphatase,
protease, and CP inhibitor cocktails and stored at −80° C until use.

4.2.3 Western blot analysis- human biospecimens. Samples were loaded in equal
amounts onto pre-cast 4-20% gradient gels (Bio-Rad), resolved using SDS-PAGE and
electrophoresis, and transferred onto polyvinylidene difluoride membranes (PVDF) for
semiquantitative Western blot. In brief, membranes were blocked using I-Bloc (Tropix)
and incubated overnight at 4°C in the following primary antibodies. mouse anti-total
Cx43 (1:5,000; Santa Cruz), mouse anti-dephosphorylated Cx43 (1:500; Invitrogen), and
mouse anti-Na+,K+-ATPase (1:10,000; Abcam). The Invitrogen antibody is a particularly
useful tool as it specifically recognizes connexin43 that is dephosphorylated at Ser368,
which has been shown to be a CN-sensitive target and is our primary residue of interest.
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Primary antibodies were tagged with HRP-conjugated secondary antibodies (1:10,000),
and developed using ECL-plus Western kit (GE Healthcare). Protein levels were
quantified on the Storm Phosphor Imager (GE Healthcare). Signal intensity for resultant
bands was calculated, and all protein signals were normalized to internal control (i.e.
Na+,K+) bands.

4.2.4 Primary astrocyte culture. Primary astrocyte cultures were prepared from E18
Sprague Dawley rat pups similar to that described previously (Sama et al. 2008; Furman
et al., 2010). Animals were treated in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals. In brief, fetal cortical tissue was
harvested and washed in Hanks Balanced Salt Solution before trypsinization and
mechanical dissociation by trituration. Cells were plated in culture flasks in Minimal
Essential Medium (MEM), buffered by NaHCO3, and supplemented with L-glutamine,
1% antibiotics/antimitotics, and 10% fetal bovine serum. Astrocyte cultures were grown
to 80–90% confluency (typically 10–12 days), and microglia were removed by vigorously
shaking the flasks at room temperature for 30 min on an orbital shaker [Keller et al.
1996]. Cells were trypsinized and replated with fresh medium in 35-mm culture dishes
and grown to ~90% confluency. Previous immunocytochemical analyses of our cultures
have indicated that fewer than 5% of plated cells label positively for the microglial marker
Iba-1 (data not shown). For a serum-free environment, regular medium was replaced
with serum-free medium (MEM, N2, and gentamicin) immediately prior to the start of
experiments.

4.2.5 Culture treatments and collection. At approximately 24 h before collection,
astrocyte culture dishes were washed 2x with phosphate-buffered saline and switched
into serum-free media. For all culture experiments, approximately 16 h prior to collection,
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either CsA (10µM; Millipore) or 43Gap52 (1µM; RS Synthesis [described further in
background]) were added to inhibitor condition dishes. For EtBr uptake assay, either CN
auto-inhibitory peptide (CNAIP) (50μM; Millipore) was added in addition to CsA or
43

Gap52. Approximately 3-5 h prior to collection, dishes in CN-stimulating conditions

were exposed to 10ng/mL IL-1β. For Western blot analysis, the exogenous Ca2+mobilizers ionomycin (Ion) (1µM; Sigma) and phorbol ester (PE) (1µM; Sigma) were also
applied to culture dishes.
For Western blot analysis, cultures were homogenized in 30% sucrose buffer containing
a panel of phosphatase and protease inhibitors as described (Sama et al., 2009; Furman
et al, 2010) and scraped free into Eppendorf tubes. Cell lysates from each dish were
stored at -80°C until use.
For NFAT-Luciferase assay endpoint measurements, cells were infected with Ad-NFATLuc approximately 24 h prior to collection at multiplicity of infection (MOI) of 100. At an
MOI of 100, more than 90% of all astrocytes are infected within each dish, ensuring
uniform distribution of the NFAT-reporter construct across treatment groups. To collect
cell lysates, each culture dish was washed two times with phosphate-buffered saline,
and then cells were scraped free in mammalian protein extract reagent (M-PER) buffer
(Thermo Fisher) into Eppendorf tubes. Cell lysates from each 35-mm dish were stored at
-20°C until use.

4.2.6 Western blot analysis- primary astrocyte culture. Equal amounts of protein
using the Lowry method were loaded into individual wells of Criterion TGX pre-cast 4–
20% gradient gels (Bio-Rad) and resolved using SDS-PAGE. Proteins were then
transferred to polyvinylidene difluoride membranes for semi-quantitative Western blot
analysis using the Odyssey Sa Imager System. Membranes were pre-blocked with
Odyssey Blocking Buffer and incubated overnight in blocking buffer plus primary
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antibodies as described above for the blots with human samples. Primary antibodies
were tagged with IRDye-conjugated fluorescent secondary antibodies (1:15,000 [800] or
1:20,000 [680]; Li-Cor), and near-infrared signal was detected on the Odyssey Sa
Imager System (Li-Cor). Signal intensity for resultant bands was calculated, and all
protein signals were normalized to internal control (i.e. Na+,K+) bands.

4.2.7 NFAT-luciferase reporter assay. As a control for potential between-group
variability in NFAT-luciferase expression, all sample volumes were normalized to the
same protein concentration with TCM buffer using the Lowry method. Luciferase
expression was quantified using a luciferase detection kit (Luc Screen; Tropix) and a
plate reader. Typically, six or more dishes were analyzed per treatment condition and
experiment was repeated in triplicate, resulting in a well powered experimental design.

4.2.8 Ethidium bromide dye uptake assay. To assess hemichannel permeability, cells
were exposed to 5µM ethidium bromide (EtBr; Fisher) for 10 min, washed 2x with
phosphate-buffered saline, and immediately imaged on an inverted fluorescent
microscope [Nikon Eclipse TE200 with Nuance FX Multispectral Imaging System].
Typically, three or more dishes were analyzed per treatment condition and experiment
was repeated in triplicate, resulting in a well powered experimental design. For analysis,
total fluorescence intensity was calculated using Adobe Photoshop.

4.2.9 Statistics. ANOVA was used to compare differences in Western blot protein
levels. Average luciferase and ethidium bromide values were compared with repeated
measures ANOVA. When appropriate, Fisher's protected least significant difference test
was used for post hoc analyses. Significance for all statistical comparisons was set at p
≤ 0.05.
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4.3 Results
4.3.1 Levels of dephosphorylated Cx43 are elevated early in the progression of AD
and are positively correlated with increased CN activity.
Studies from other labs have demonstrated raised levels of dephosphorylated Cx43 with
neuroinflammation or other insults e.g. hypoxia. To assess levels of dCx43 through the
progression of AD, we used human hippocampal biospecimens from confirmed cases of
Mild Cognitive Impairment (MCI), AD, as well as age-matched non-demented controls
(ND). All samples were obtained with a rapid post-mortem autopsy interval (approx. 3
hours) and were extensively characterized for AD pathology i.e. Braak stage, MMSE
score by a neuropathologist. Using an antibody that recognizes the entire Cx43 protein,
Western blot analyses revealed a small, non-significant reduction in total Cx43 levels in
MCI cases relative to ND control cases (Fig 4.1A). Further, using an antibody that
specifically recognizes the Cx43 protein when it’s dephosphorylated at serine368 (CNsensitive residue), Western blot analyses revealed a significant increase (p < 0.01) in
dCx43 levels in samples from MCI cases relative to ND control samples (Fig 4.1B).
Thus, comparing the ratio of dCx43 to total Cx43 we see a significant increase (p <
0.001) in MCI cases relative to ND control cases (Fig 4.1C).
Using samples from the same cases, we measured protein levels of ΔCN, a
constitutively active CN fragment, in cytosolic fractions as well as protein levels of
NFAT1, a downstream CN target, in nuclear fractions. With ranked levels of dCx43, we
observed significant positive correlations with both CN activation (ΔCN) (p < 0.05) (Fig
4.1D) and CN activity (NFAT1 translocation) (p < 0.01) (Fig 4.1E). These results indicate
that dCx43 are elevated in early stages of AD in a CN-dependent manner.
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4.3.2 Levels of dephosphorylated Cx43 are elevated under CN-stimulating
conditions in rat primary astrocyte cultures, and are blocked with the use of CN
inhibitors.
To mimic the results we observed in the human biospecimens, we performed Western
blot analyses using rat primary astrocyte cultures. Conditions of elevated CN activation
were achieved with the application of exogenous Ca2+ mobilizers, ionomycin (Ion) and
phorbol ester (PE), as well as the endogenous neuroinflammatory factor, interleukin 1
beta (IL-1β). Similar to our human data, with both Ion/PE (Fig 4.2, left panels) and IL-1β
(Fig 4.2, right panels) we saw a reduction in levels of total Cx43 (Fig 4.2 A,D) and a rise
in levels of dCx43 (Fig 4.2, B,E) under conditions of CN stimulation relative to untreated
controls. This resulted in significant increase (p < 0.05) in dephosphorylated-to-total
Cx43 ratio after treatment with both Ion/PE and IL-1β (Fig 4.2 C,F). This effect was
inhibited using the CN inhibitor, cyclosporin A (CsA) (Ion/PE, data not shown; IL-1β, see
Fig 3). These results reinforce that the trends we see in our human data i.e. levels of
dCx43 increase in tandem with CN proteolysis and activity, and can be replicated using
a primary astrocyte culture system.

4.3.3 A mimetic peptide that encompasses Serine 368 on the C-terminus of Cx43
blocks dephosporylation of Cx43 but does not interfere with other CN substrates.
To determine if our mimetic peptide (43Gap52) could prevent dephosphorylation of Cx43
we performed Western blot analyses using rat primary astrocyte cultures stimulated IL1β. Inhibition of the inflammatory mediatior, IL-1β, with both CsA and 43Gap52 blocked
dephosphorylation of Cx43 (p < 0.05) (Fig 4.3 A,B). Moreover, to ensure that 43Gap52
does not interfere with other CN substrates e.g. Nuclear factor of activated T cells, we
did an NFAT-luciferase reporter assay. Application of CsA to primary astrocyte cultures
treated with IL-1β revealed a significant reduction in luciferase expression (p < 0.05) (Fig
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4.3 C), but application of 43Gap52 did not reduce luciferase expression (Fig 4.3 D).
Together, these results suggest that 43Gap52 sufficiently reduces dephosphorylation of
Cx43, and is relatively selective for CN/Cx43 interactions.

4.3.4 Hemichannel permeability is reduced using CN-AIP and 43Gap52 in primary
astrocyte cultures treated with IL-1β.
To assess hemichannel permeability, we performed ethidium bromide (EtBr) dye uptake
assays in primary astrocyte cultures treated with IL-1β. Culture dishes with no EtBr
treatment served as a negative control, and imaging revealed uniform auto-fluorescence
but no uptake into the nuclei of cells (data not shown). Application of IL-1β resulted in
significant EtBr uptake into cells (Fig 4.4 A, top right) versus untreated (UT) conditions (p
< 0.001) while pre-treatment with both the CN-AIP (p < 0.01) or 43Gap52 (p < 0.001) had
reduced EtBr uptake into cells (Fig 4.4 A, bottom panels). These results suggest that
CN/Cx43 interactions lead to increased hemichannel permeability in astrocytes which
may negatively impact synaptic function and neuronal viability.

4.4 Discussion
In this present study, levels of connexin43 dephosphorylation were elevated in both
human MCI tissue and rat primary astrocyte cultures that had been treated with CN
stimulators. Further, a novel mimetic peptide (43Gap52) was used as a potentially
selective inhibitor for CN/Cx43 interactions. Lastly, ethidium bromide uptake assays
revealed increased dye uptake under conditions of CN activation. Together, results
suggest that CN/Cx43 interactions may have a major impact on the function of activated
astrocytes and their role in synaptic maintenance.
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4.4.1 Dephosphorylation of Cx43 in AD progression
CNS injury and disease (e.g. Alzheimer’s disease) are associated with changes in
connexins, including connexin43 (Cx43), which is the most abundant connexin
expressed in astrocytes (Orellana et al., 2009; Koulakoff et al., 2012; Orellana et al.,
2012). Moreover, a specific residue on the C-terminus of Cx43, Ser368, is sensitive to
CN (Li and Nagy, 2000; Tence et al., 2012). Work from our lab, and others, have shown
CN expression and activation of downstream targets (i.e. NFATs) is elevated with
Alzheimer’s disease (Hashimoto et al., 1998; Norris et al., 2005; Celsi et al., 2007; Abdul
et al., 2009; Serrano-Perez et al., 2011; Neria et al., 2013; Furman et al., 2016; Pleiss et
al., 2016). Consistent with these findings, the present study found elevated levels of
dephosphorylated Cx43 in both primary astrocyte cultures and human MCI hippocampus
in tandem with elevations in CN activity (Figs 4.1 and 4.2). These results suggest
CN/Cx43 interactions may play a significant role in the initiation or progression in the
early stages of AD (i.e. MCI).
Surprisingly, in human tissue, levels of dephosphorylated connexin43 were
reduced to control levels (Fig 4.1 B). One possibility for this reduction is that AD tissue
can have variable levels of both Aβ and NFT pathology, which could mask any trends in
levels of dephosphorylated Cx43. Future studies to measure protein levels of
dephosphorylated Cx43 across the course of AD (i.e. mild, moderate, severe) could help
elicit the trend in Cx43 dephosphorylation. An alternative possibility is that tissue is too
severely degenerated in AD cases to get a true measurement of dephosphorylated Cx43
levels. Regardless, the elevations in dephosphorylated Cx43 in MCI tissue suggest that
potential therapeutics should be delivered early in the disease progression.
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4.4.2 Use of the novel mimetic peptide, 43Gap52
Inhibition of CN using general inhibitors (e.g. cyclosporin A or FK506) can have
beneficial effects for neurons and astrocytes, such as improved synaptic function
(Taglialatela et al., 2009). However, not only is general inhibition of CN non-specific,
there are also many adverse side effects, including nephrotoxicity and
immunosuppression (Reese and Taglialatela, 2011; Taglialatela et al., 2015). We have
previously shown that use of a selective CN/NFAT inhibitor (VIVIT) delivered to
astrocytes in models of CNS injury and disease results in improved synaptic function
(Furman et al., 2012; Furman et al., 2016; Sompol et al., in preparation), improved
cognitive performance (Furman et al., 2012; Sompol et al., in preparation), and reduced
glial activation (Furman et al., 2012). Using this rationale, in the present study we
developed a small mimetic peptide to the C-terminus of Cx43 encompassing the CNsensitive residue, Ser368 (named 43Gap52) to act as a “decoy” substrate. While 43Gap52
significantly reduced levels of dephosphorylated Cx43 in primary astrocyte culture (p <
0.05) (Fig 4.3 B), it did not inhibit expression of NFAT-luciferase (Fig 4.3 D), suggesting
the 43Gap52 is relatively selective at inhibiting CN/Cx43 interactions.
While the preliminary evidence is encouraging, the peptide is 52 residues in
length (including 11 poly-Arg and 3 Gly linker residues to facilitate cellular uptake).
Additionally, studies were performed in primary astrocyte culture and human tissue, but
no in vivo studies using 43Gap52 have been performed. Future studies should first focus
on refining 43Gap52 to reduce the peptide length but only to the extent that it is still
effective at inhibiting CN/Cx43 interactions. Next, 43Gap52 could be put into an AAV
vector with a Gfa2 promotor so that it could be delivered specifically to astrocytes in
transgenic AD mouse models or HHcy diet-induced mouse models of VCID. The in vivo
studies using 43Gap52 could measure synaptic function and plasticity, cognition, and
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protein levels of dephosphorylated Cx43. Overall, the preliminary evidence for selective
CN/Cx43 inhibition in the present study is encouraging for future in vivo studies.

4.4.3 Modulation of Cx43 hemichannes: implications for synaptic function
Hemichannels (HCs) are composed of connexin hexamers that are unopposed in the
plasma membrane, and facilitate critical cross-talk between the cytosol and the
extracellular milieu. Normally maintained in a closed state, HCs can significantly alter the
composition of the astrocyte cytosol (via passage of glutamate, ATP, Ca2+) when open
(Takeuchi and Suzumura, 2014; Moore and O’Brien, 2015; Olsen et al., 2015).
Alterations in HCs in astrocytes have been implicated in several neurological disorders,
including epilepsy (Seifert et al., 2010; Steinhauser et al., 2012) and neurodegeneration
(Seifert et al., 2006; Rossi and Volterra, 2009; Quintanilla et al., 2012). Moreover,
previous studies have not only found that AD-relevant factors can increase hemichannel
activity in astrocytes but these astrocyte hemichannels also release neurotoxic factors
such as glutamate (Orellana et al., 2011 a,b). Consistent with these findings, the present
study found that application of IL-1β to primary astrocyte cultures resulted in increased
ethidium bromide dye uptake (p < 0.001) (via Cx43 HCs) and this uptake was impaired
using a CN auto-inhibtory peptide (p < 0.01) and 43Gap52 (p < 0.001) (Fig 4.4).
While the results show that inhibition of CN/Cx43 interactions in astrocytes using
43

Gap52 can have an effect on HCs, it is still unclear what effect HC modulation has on

synaptic function. Finding a way to study this in vivo, possibly through an AAV vector
(see above), will be critical for understanding the consequences of CN/Cx43 inhibition on
synaptic function. In addition to obtaining electrophysiological outcomes of synaptic
function and plasticity (i.e. basal synaptic strength and LTP), outcome measurements
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could also include protein levels of synapse-relevant proteins (e.g. PSD-95, synapsin 1,
GluR1, and NR2A/NR2B) (Ansari et al., 2013; Scheff et al., 2013; Furman et al., 2016).
Regardless, this study provides encouraging proof-of-concept results for inhibition of
CN/Cx43 interactions and provides rationale for studying synaptic function in vivo.
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Human Subjects
Group
Classification
Control
(ND)

n

m/f
2/10

Age
(years)
87.8 ± 0.7

PMI
(hours)
2.9 ± 0.6

Braak
Stage
0.83 ± 1

12

Mild
Cognitive
Impairment
Alzheimer’s
disease

MMSE
29.1 ± 1.3

9

4/5

89.8 ± 5.7

3.9 ± 2.4

3.4 ± 1.2

23.8 ± 3.9

15

6/9

79.1 ± 7.1

3.4 ± 0.87

5.7 ± 0.8

8.3 ± 7

Table 4.1 Description of human subject tissue from non-demented control, mild
cognitive impairment, and Alzheimer’s disease cases. Values expressed as Mean ±
SD. PMI= postmortem autopsy interval. MMSE= mini mental state examination.
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Figure 4.1 Levels of dephosphorylated connexin43 are elevated in MCI in tandem
with increased CN activity. Representative bands and Mean ± SEM Cx43 (A) total
Cx43, (B) Ser368 dephosphorylated Cx43 (p < 0.01), and (C) dephosphorylated:total
Cx43 (p < 0.001) protein levels in human hippocampal tissue. Phosphorylation state
changes markedly in MCI samples, but is not apparent in AD samples. Dephospho-Cx43
shows a significant positive correlation with the constitutively active form of CN (D) and
to activated NFAT1 (E), a CN-dependent transcription factor.
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Figure 4.2 Levels of dephosphorylated connexin43 are elevated in rat primary
astrocyte cultures treated with endogenous and exogenous stimulators of CN
activity. Representative bands and mean ± SEM total Cx43 (A,D) and
dephosphorylated Cx43 (B,E) protein levels normalized to Na+/K+ ATPase protein levels
in primary astrocyte cultures treated for 1 hr with Ion/PE (Left panels) or IL-1β (Right
panels). Stimulation of astrocytes with each treatment resulted in a significant increase
in the ratio of dephosphorylated Cx43 to total Cx43 (p < 0.05) (C,F).
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Figure 4.3 A decoy mimetic peptide, 43Gap52, selectively inhibits CN/Cx43
interactions. Representative bands and Mean (% control) ± SEM dephosphorylated
protein levels of primary astrocyte cultures treated with IL-1β in the presence or absence
of CsA (p < 0.05) (A), or 43Gap52 (p < 0.05) (B). Mean (% control) ± SEM NFATluciferase expression levels of primary astrocyte cultures treated with IL-1β in the
presence or absence of CsA (p < 0.05) (C), or 43Gap52 (D).
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Figure 4.4 The mimetic peptide 43Gap52 reduces ethidium bromide dye uptake into
primary astrocyte cultures. 10x photomicrographs of EtBr uptake in UT p7 astrocytes
(A, top left panel) and astrocytes treated for 3 h with 10 nM IL-1β (A, top right panel)
with/without CN-AIP (A, bottom left panel), or 43Gap52 (A, bottom right panel). (B)
Mean+SEM EtBr uptake. Experiment was done in triplicate.
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CHAPTER V: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS
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5.1 General Conclusions
Aging, injury, and neurodegenerative diseases have a unifying hallmark of
neuroinflammation, characterized by neuroglial reactivity and a significant upregulation
of cytokines, reactive oxygen species, and nitric oxide (Akiyama et al., 2000; Kitazawa et
al., 2004; Skaper, 2007). Astrocytes, in tandem with microglia, help to coordinate the
neuroinflammatory response which may be advantageous in an acute setting but
detrimental under chronic conditions (Akiyama et al., 2000; Wyss-Coray and Mucke,
2002; Skaper, 2007; Meraz-Rios et al., 2013). Furthermore, under pathological
conditions activated astrocytes not only undergo increased production of proinflammatory mediators but also lose or see a significant weakening in the regulation of
critical, normal astrocyte functions (e.g. synaptic maintenance) (Fuller et al., 2009;
Sofroniew and Vinters, 2010; Steele and Robinson, 2012). Several astrocyte signaling
pathways have been implicated in neurodegeneration and one in particular, the protein
phosphatase calcineurin, may help initiate and/or promote the activated astrocyte
response (Norris et al., 2005; Fernandez et al., 2007; Canellada et al., 2008; Sama et
al., 2008; Abdul et al., 2009; Furman et al., 2012; Pleiss et al., 2016). Moreover, aberrant
Ca2+ dysregulation that is often seen in neurodegeneration may result in proteolysis of
calcineurin that unregulated, constitutively active, and generally deleterious to cellular
and synaptic function (Wu et al., 2004; Pleiss et al., 2016). Thus, astrocytic calcineurin
signaling—both activation of and interactions with downstream targets is an ideal
molecular target for modulating the harmful effects of activated astrocytes with
neuroinflammation and neurodegeneration.
The all-encompassing goal of this dissertation was to explore calcineurin
signaling in astrocytes in a variety of neurodegenerative conditions that share a
neuroinflammatory hallmark. Using a novel antibody (ΔCN), we determined that highly
active, proteolyzed calcineurin is abundant in astrocytes, especially those closely
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associated with AD and vascular pathology (Chapter II) (Pleiss et al., 2016). A previous
study using adeno-associated virus (AAV) to deliver an inhibitor of CN/NFAT signaling—
VIVIT—specifically to astrocytes in APP/PS1 mice revealed reduced glial activity and
amyloid deposition, as well as improved synaptic function and cognitive performance
(Furman et al., 2012). Using the same strategy in a diet-induced mouse model of VCID,
we determined that inhibition of CN/NFAT in astrocytes was synaptoprotective but had
no significant effect on cognitive performance (Chapter III). To explore other possible
downstream targets, we looked at interactions between CN and Cx43 in AD. Using a
novel mimetic peptide ‘decoy’ (43Gap52) to the C-terminus of Cx43, we determined that
we could inhibit dephosphorylation of Cx43 without inhibiting CN’s effects on other
targets. Moreover, application of 43Gap52 resulted in a functional normalization of Cx43
hemichannel function (Chapter IV) (Pleiss et al., in preparation). Taken together, these
results suggest that both CN activation and its interactions with downstream targets in
astrocytes can significantly contribute to neurodegenerative disease (i.e. AD and VCID)
processes, and therefore provides a valuable molecular target for therapeutics.

5.2 The big picture: is astrocytic calcineurin a good therapeutic target for
neurodegenerative diseases?
The section above provides the rationale for why I chose to study calcineurin signaling in
astrocytes for this dissertation, but it is possible that this may not be the best target for
neurodegenerative disease therapeutics. Here, I will explore three possibilities where
targeting of astrocytic calcineurin signaling may not be effective or may even be harmful
to cells in the brain.
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5.2.1 Alternative cell types
While our previous work and the work in this dissertation presents strong evidence that
inhibition of astrocytic CN is synaptoprotective (Furman et al., 2012; Furman et al., 2016;
Sompol et al., in preparation), improves cognitive function (Furman et al., 2012; Sompol
et al., in preparation), and reduces glial activation (Furman et al., 2012), it is possible
that inhibition of CN signaling in other cell types (e.g. neurons or microglia) may be a
more effective therapeutic. One study in AD transgenic mice revealed that acute, blanket
inhibition of CN (which would include neurons and astrocytes) resulted in improved
cognition (Dineley et al., 2007). Moreover, another study found that inhibition of CN in
cortical cultures provided the neuroprotective effect of maintaining nitric oxide synthase
catalytic activity (Dawson et al., 1993). Additionally, a recent study revealed that
inhibition of NFAT—an almost exclusive substrate of CN-- in microglia, both in vitro and
in a transgenic AD model, provides a robust anti-inflammatory effect (Rojanathammanee
et al., 2013). A study that inhibited CN in oligodendrocytes saw a reduction in apoptosis
(Sanchez-Gomez et al., 2003). Therefore, it is certainly plausible that astrocytes are not
the only viable neural cell type where CN inhibition is protective.
Initial future studies in our lab could focus on putting VIVIT or 43Gap52 into AAV
vectors with neuronal-specific, microglial-specific, or oligodendrocyte-specific promoters
to study the in vivo effect of CN inhibition in alternative neural cell types. Outcomes
measures should include cognitive testing, synaptic transmission and plasticity, as well
as protein/RNA measurements of glial activation and neuroinflammation. While multiple
studies (including ours) have already established that inhibition of astrocytic CN provides
cognitive and synaptic benefits, I think the next big obstacle to overcome in
neuroscience research is dissecting the differences in phenotype between healthy and
diseased tissue, and furthermore in response to different types of CNS injury and insult.
In fact, a recent study in the Barres lab has started to explore this in healthy versus
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diseased astrocytes in response to two different CNS insults (Zamanian et al., 2012),
and I will elaborate on this more in section 5.2.2. This consideration is critical because
many studies operate under the notion that all cells (e.g. all astrocytes) respond to
disease insults uniformly when in fact the results in this dissertation (Fig 2.2 K, Fig 2.5)
as well as other studies (e.g. Zamanian et al., 2012) suggest otherwise. Once these
phenotypic differences are better understood, not only will we be able to target
therapeutics to specific cell types, but we can hopefully target the specific cell
phenotypes that exhibit detrimental properties (i.e. contribute to the disease processes)
and at the same time maintain cells that are neuro-protective (i.e. function normally).

5.2.2 Is CN activity protective?
Our previous work and the work in this dissertation have established that exacerbated
activation of CN is detrimental to synapses (Pleiss et al., 2016) and that inhibition of CN
in astrocytes provides synaptic and cognitive benefits (Furman et al., 2012; Furman et
al., 2016; Sompol et al., in preparation). However, it is possible that there are instances
in which CN activation may be beneficial. First, time and duration of CN activity must be
considered. In an acute setting, activation of CN and the glial response may be
advantageous for isolating invading pathogens and/or sites of tissue damage. In fact, a
study that examined the response of astrocytes to acute (ischemic) versus chronic
(neuroinflammatory) insults found that astrocyte activation in acute injury is
overwhelmingly protective and functions to repair the BBB, limits immune cell influx, and
decreases neuronal cell death (Zamanian et al., 2012). Ignoring disease for a moment
and focusing on healthy tissue, studies have shown that CN is abundant in neurons and
plays a critical role in the maintenance of neuronal structure and function (e.g. dendritic
spines and synaptic plasticity, respectively) (Halpain et al., 1998; Wu et al., 2010).
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Moreover, outside of the CNS, calcineurin can play important roles in skeletal muscle
differentiation (Friday et al., 2000) or Schwann cell differentiation (Kao et al., 2009).
On the contrary, while CN activation certainly has protective and beneficial
functions in some cases, in chronic neurodegenerative conditions such as AD or VCID-which are the focus of this dissertation-- I think that increased CN activity is
tremendously harmful. For instance, acute inhibition of CN in Tg2576 mice restored
cognitive deficits (Taglialatela et al., 2009) or inhibition of CN in an acute model of CNS
injury was incredibly synaptoprotective (Furman et al., 2016). Moreover, chronic
activation of CN/NFAT-dependent transcription of pro-inflammatory factors are
associated with neurodegeneration (Van Wagoner et al., 1999; Fernandez et al., 2007;
Sama et al., 2008). Additionally, a study that observed the response of astrocytes to a
neuroinflammatory response found that activation of astrocytes in this instance was
overwhelmingly detrimental through inhibition of axonal regeneration, secretion of proinflammatory factors, and activation of the complement cascade that ultimately
contributes to synapse loss (Zamanian et al., 2012). Therefore, the focus on targeting
CN-mediated astrocyte activation in these dissertation studies was on point; however, as
mentioned in section 5.2.1, future studies should focus on better understanding
astrocyte phenotypes in response to different CNS insults and diseases.

5.2.3 Non-calcineurin targets
While inhibition of CN in astrocytes has been shown to provide numerous cognitive and
synaptic benefits (Furman et al., 2012; Furman et al., 2016; Sompol et al., in
preparation), perhaps there are alternative, more effective therapeutic targets available.
Many studies aimed at clearing or reducing Aβ levels in Alzheimer’s disease have been
performed, yet none have provided compelling evidence for cognitive improvement due
to reduction of beta-amyloid levels (Rosenblum, 2014). A therapeutic aimed at general
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neuroinflammation and/or specific componenets may be beneficial. For example, one
study revealed a lessened inflammatory response and reduction in Aβ levels in APP/PS1
mice using intravenous immunoglobin, a general immune modulator (Sudduth et al.,
2013 a). Many different studies have explored the use of non-steroidal anti-inflammatory
drugs (NSAIDs) as a therapeutic for AD and other diseases with neuroinflammatory
components, and while people that are on long-term NSAID regimens have a reduced
risk of developing AD (Andersen et al., 1995; Rich et al., 1995; McGeer et al., 1996; Lee
et al., 2010), controlled trials have not been able replicate these beneficial effects (Aisen
et al., 2003; Reines et al., 2004). Furthermore, recent studies have revealed that
upregulation of reactive oxygen species and reactive nitrogen species may contribute to
neurodegenerative disease, and thus may provide a good therapeutic target (Nakamura
et al., 2013). Alternatively, reduction of aberrant tau using an inhibitor to a specific heat
shock protein revealed improved synaptic function in vivo (Abisambra et al., 2013). So
while many non-CN targets exist and may be advantageous, the benefit of targeting CN
is that Ca2+ dysregulation is a common denominator in many neurodegenerative
diseases, and therefore therapeutics aimed at CN inhibition could be targeted to a broad
spectrum of diseases. However, many complex and multi-factorial processes are
occuring in neurodegeneration, and as such, I think that CN inhibition in tandem with
other therapeutics (e.g. Aβ clearance) will provide the most beneficial results.

5.3 Concluding Remarks
The work in this dissertation has presented a broad picture of astrocytic calcineurin
activation and its interactions with downstream targets in several neurodegenerative
diseases. Using a novel antibody, I have shown that constitutively active, proteolyzed
CN is found in astrocytes strongly associated with both AD and vascular pathology.
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Additionally, using AAV-mediated astrocyte-specific inhibition of CN/NFAT in a mouse
model of VCID revealed synaptoprotective effects. Furthermore, a novel “decoy” mimetic
peptide to the C-terminus of Cx43 was able to selectively interact CN/Cx43 interactions
and functionally normalize hemichannels in rat primary astrocyte cultures. Together, this
suggests the astrocytic CN signaling pathways are not only a major player in
neurodegenerative disease processes but should also be considered a viable target for
AD and VCID therapeutics.
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